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Preface 
This report describes in detail the methodology for a case study-based review of 29 
cardiovascular and stroke research grants, funded in three countries between 1989 and 
1993. The case studies focused on the individual grants but considered the development of 
the investigators and ideas involved in the research projects from initiation to the present 
day. Basic biomedical and clinical cardiovascular and stroke research grants awarded in 
Australia, Canada and the UK were selected through a stratified random selection 
approach that aimed to include both high- and low-impact grants. The structured case 
studies were used to assess the impact of these grants in detail and to draw conclusions 
about the relationship between impact and a range of factors. The key messages from the 
project are as follows. 
•  The cases reveal that a large and diverse range of impacts arose from the 29 grants 
studied. 
•  There are variations between the impacts derived from basic biomedical and 
clinical research. 
•  There is no correlation between knowledge production and wider impacts. 
•  The majority of economic impacts identified come from a minority of projects. 
•  We identified factors that appear to be associated with high and low impact. 
This report presents the project’s methodology in detail. The Policy Report
1 presents the 
project’s findings and their implications for policy, and the Case Study report
2 presents all 
29 case studies carried out. 
This work was led by RAND Europe in collaboration with the Health Economics 
Research Group (HERG) at Brunel University. RAND Europe is an independent not-for-
profit policy research organisation that serves the public interest by improving policy-
making and informing public debate. The Health Economics Research Group is a 
Specialist Research Institute of Brunel University dedicated to conducting accessible, 
policy-relevant research of a high academic quality focused on improving the efficiency and 
cost-effectiveness of resources devoted to health care and to research. This report has been 
                                                       
1 Wooding, S., S. Hanney, A. Pollitt, M. Buxton, and J. Grant. Project Retrosight. Understanding the returns 
from cardiovascular and stroke research: Policy Report. Cambridge, UK: RAND Europe, MG-1079-RS, 2011. 
2 Pollitt, A., S. Wooding, S. Hanney, M. Buxton, and J. Grant. Project Retrosight. Understanding the returns 
from cardiovascular and stroke research: Case Studies. Cambridge, UK: RAND Europe, WR-836-RS, 2011. Project Retrosight: Methodology Report  RAND Europe 
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peer-reviewed in accordance with RAND’s quality assurance standards
3 and therefore may 
be represented as a RAND Europe product. 
For more information about RAND Europe or this document, please contact: 
Steven Wooding 
Research Leader 
RAND Europe 
Westbrook Centre, Milton Road 
Cambridge, CB4 1YG 
United Kingdom 
Email: wooding@rand.org or reinfo@rand.org 
                                                       
3 RAND Europe: see http://www.rand.org/about/standards/ [Accessed 16 December 2010]   
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CHAPTER 1  Introduction 
Project Retrosight was a multinational study that investigated the translation and payback 
from basic biomedical and clinical cardiovascular and stroke research projects. The main 
project aims were to: 
•  examine the variety of payback produced by basic biomedical and clinical 
cardiovascular and stroke research; 
•  identify factors associated with high (and low) levels of payback, in particular 
factors relating to the characteristics of the research, how it was supported or the 
context in which it was carried out; 
•  examine the significance of country context in the process of translation and 
production of payback. In the event it did not prove possible to carry out cross-
country analysis (discussed in the Policy Report, Wooding et al., 2011). 
These basic aims informed all methodological decisions made during the project. This 
report describes the methodology in detail, working through the project stage by stage.  
The resulting analysis is based on a series of 29 case studies of basic biomedical and clinical 
cardiovascular and stroke research project grants in Australia, Canada and the UK. Each 
case study focuses on a single project grant awarded to a researcher during the selected time 
window of 1989–93 and follows the process that led from the application for the grant and 
its subsequent award, through the research that followed and the outputs emanating from 
it up to the present day. A standard case study selection process was used for each grant in 
each of the three countries. 
Our analysis compared the payback for each grant and enabled us to draw out common 
factors associated with impact. The five key findings, which are explored in detail in the 
Policy Report (Wooding et al., 2011), are as follows. 
1.  The cases reveal that a large and diverse range of impacts arose from the 29 
grants studied. 
2.  There are variations between the impacts derived from basic biomedical and 
clinical research. 
3.  There is no correlation between knowledge production and wider impacts. Project Retrosight: Methodology Report  RAND Europe 
2 
4.  The majority of economic impacts identified come from a minority of 
projects. 
5.  We identified factors that appear to be associated with high and low impact. 
1.1  Summary of methods 
A summary of the Project Retrosight approach is presented in Figure 1.1. In this report we 
discuss each stage in turn, starting with how we selected our methods and identified the 
body of research to examine. We then step through the stages of our approach: collating 
lists of research grants for possible case study; estimating the payback of each grant through 
a survey of principal investigators (PIs); selecting a random stratified sample of grants for 
case study; building those case studies; quantifying the payback in each; and finally 
identifying common factors associated with payback. RAND Europe  Introduction 
3 
Figure 1-1: A diagrammatic summary of the project methods 
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CHAPTER 2  Framing issues 
2.1  Introduction 
Before beginning our research, we had to resolve a number of “framing issues” – 
fundamental decisions that would define the parameters of our study. In this section we 
describe these framing issues, explaining: 
•  the origins of the project; 
•  the decision to adopt a case study approach; 
•  the origin and application of the Payback Framework; 
•  why we chose the 1989–93 time window; 
•  how we decided which aspects of research to concentrate on. 
2.2  Project origins 
The project was inspired by series of conversations between Martin Buxton of the Health 
Economics Research Group at Brunel University (HERG) and Jonathan Grant of RAND 
Europe during breaks in a 1999 workshop on “research impact” organised in Banff, 
Canada, by the Alberta Heritage Foundation for Medical Research (now Alberta Innovates 
- Health Solutions). Interest in carrying out a study in the cardiovascular field in Canada 
was sparked by a similar study conducted by the project team in arthritis (Wooding et al., 
2004, 2005), the results of which were presented by Steven Wooding at an event hosted by 
the Canadian Institutes of Health Research (CIHR) and attended by Sally Brown of the 
Heart and Stroke Foundation of Canada. 
Assembling a consortium to support this multi-country study was time-consuming, and it 
was not until 2007 that work finally started on the project, as a joint undertaking between 
HERG and RAND Europe, with support from the CIHR, the Heart and Stroke 
Foundation of Canada, the National Heart Foundation of Australia, the UK National 
Institute of Health Research, the UK Stroke Association and the British Heart Foundation. 
The project was managed by RAND Europe and UK case studies were carried out by 
researchers from both RAND and HERG. Canadian case studies were carried out by an in-
house team of researchers from the CIHR while Australian case studies were conducted by 
a team comprising an internal staff member of the National Heart Foundation of Australia 
and a specialist consultancy, Instinct and Reason. Project Retrosight: Methodology Report  RAND Europe 
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Bibliometric analysis for the project was coordinated by Linda Butler of the Research 
Evaluation and Performance Project at the Australian National University and data 
analysis was carried out in collaboration with Thed van Leeuwen of the University of 
Leiden’s Centre for Science and Technology Studies (CWTS). 
2.3  The case study approach 
We chose the case study approach because we wanted to understand each grant and its 
story in detail. As with all research methods, this approach has its advantages and 
disadvantages. In general, case studies are preferred when “how” or “why” questions are 
being proposed as they provide a rich source of material for examination (Yin, 2003). In 
the context of Project Retrosight, they provide a detailed picture of what led to the award 
of the grant, how the research progressed and how it subsequently developed. Indeed, there 
is a long history of the use of case studies to examine the translation of research into actual 
results, especially where the emphasis of a study is on showing the long-term benefits from 
health research (Hanney et al., 2004). 
For Project Retrosight the use of case studies enabled us to understand and demonstrate, in 
narrative form, how the output from research funded in the early 1990s was – or was not – 
translated into practical measures that have had an impact on healthcare and society at 
large. 
Each case study provides an overview of both the long-term and shorter-term outcomes of 
a specific piece of work. Case studies are especially useful in illuminating research 
translation because they allow detailed exploration of contextual and individual factors that 
are (or may be) significant, and that are not easily captured by macro-level analysis.  
When used for such illustrative purposes, case studies will not be representative of the 
wider research carried out at the time in a statistical sense; this would require a fully 
randomised, large-scale sample, which is simply not feasible when using an in-depth case 
study approach. Instead we have aimed to select a balance of case studies that encompasses 
the range of research taking place at the time. This was based on a number of key criteria; 
for example, we selected both basic biomedical and clinical research case studies in order to 
explore and compare the impact of these two types of research. The importance of 
achieving an appropriate balance meant that selecting suitable case studies was a critical 
stage of the research process. 
Case studies are also effective when trying to build up a picture of typical behaviour. In 
this instance, we aimed to use the case study approach to provide insights into the research 
translation process that could help to improve the management and funding of research. 
Because of this it was important that the conclusions from the case studies could be 
generalised. 
For case study research the justification for generalisation is the repetition of a finding 
across case studies rather than statistical representativeness. A finding seen in a substantial 
number of case studies can be more confidently generalised than one found in only one or 
two examples. In order to increase the power of such comparisons, the case studies on 
either side of the comparison may be selected to balance other characteristics. So, for RAND Europe  Framing issues 
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example, in a comparison of the effect of gender, comparison cases might be matched for 
the career position of the investigator. 
In contrast, survey-based studies achieve generalisability through ensuring a statistically 
representative sample of the population. However, the depth in which individual cases can 
be examined, as well as the contextual information that can be incorporated, is much more 
limited.  
The relatively large number of case studies in Project Retrosight gave us considerable 
insight and provided sufficiently robust evidence to make a variety of comparisons. In a 
study that adopts a multicase approach, the aim is to ensure that we can examine the 
benefits from different types of research and look for common factors. Using multiple case 
studies also allows us to carry out cross-case analysis from which to draw some general 
conclusions.  
2.4  The Payback Framework 
The research evaluation framework used in Project Retrosight was developed by HERG at 
Brunel University (Buxton and Hanney, 1996, 1997) and subsequently refined in 
collaboration with RAND Europe (Hanney et al., 2004). We chose to use it for this 
project because it is a proven framework for the selection and analysis of case studies in 
research evaluation.  The Payback Framework is both a tool for evaluating a range of 
potential outputs from research and additionally (unlike most other frameworks) a logic 
model that provides a mechanism for conceptualising the process through which outputs 
are created.  
The Framework consists of two components. The first is the system of classifying the 
outputs of research. It should be emphasised that the classification system is designed to 
cope with both quantifiable outcomes – for example, the number of research publications 
– and non-quantifiable impacts such as a description of career progression following the 
award of a research grant. The second component is a logic model of the research process. 
Logic models are widely used in evaluation methodology to understand input–process–
output relationships and to break down research programmes into their constituent parts. 
Originally designed for health service research in the UK, the Framework has since been 
applied in a number of contexts to evaluate payback from the funding of biomedical 
research by a Canadian organisation (Buxton and Schneider, 1999) and the analysis of 
health services research by the World Health Organisation (Pang et al., 2003). More 
recently it has been used to explore the payback from arthritis research funded by the 
Arthritis Research Council (Wooding et al., 2004) and to analyse the payback from health 
technology assessment programmes in the UK (Hanney et al., 2007) and the Netherlands 
(Oortwijn et al., 2008). The Framework has also been used to good effect in assessing 
social science, arts and humanities research (Wooding et al., 2007). 
2.4.1  Payback classification 
The evaluation framework considers five categories of impact: knowledge production, 
research targeting and capacity building, informing policy and product development, 
health and health sector benefits and broader economic benefits (described in detail 
below). A range of methods can be used to assess these individual research output Project Retrosight: Methodology Report  RAND Europe 
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categories, including expert review, bibliometric analysis, social science methods and 
economic analysis.  
Knowledge production 
The knowledge produced by research is manifested primarily through a variety of 
publications. Any type of publication can be considered, but peer-reviewed articles are 
generally thought to be the most valuable and objective measure. Other published material 
includes editorials, meeting abstracts, reviews and patent filings. Citation analysis is a 
useful tool that is often used in assessing the impact on the research field of knowledge 
emanating from a research project.  
Research targeting and capacity building 
Both these components capture benefits for future research. 
Research targeting  
The knowledge produced by a research project often influences subsequent research, 
research agendas and funding priorities, both within a specific research area and in 
complementary fields. This influence can sometimes be identified through citation 
analysis. Information about funding sources and grant sizes for a specific publication (often 
indicated in the acknowledgements section of published material) can also help win 
support for follow-on research.  
Capacity building 
A research project can contribute to building capacity within the research organisation, in 
terms of both infrastructure and staff development. For example, a project may attract 
grant support for education, training and career development. This can be manifested in 
the number of higher degrees or professional promotions awarded, the type of research 
being funded and the publication of research papers by junior researchers. Improvements 
to infrastructure might include expanding or upgrading laboratory and office facilities and 
investment in technology and equipment. 
Informing policy and product development 
Research can be used to inform policy making in a wide range of circumstances and at a 
number of levels. The impact of a piece of research on health policy making can be 
measured through interviews with key personnel and through bibliometric indicators such 
as the appearance of research citations in clinical guidelines and other policy documents. 
Research can also contribute to technological and product development, with findings 
being fed into the private sector for commercialisation. This is often achieved by licensing 
intellectual property rights or contract research work, forming public–private joint 
ventures, and through new business start-ups. 
Health and health sector benefits 
The principal payback that most health research funders aim to achieve through their 
funded research is a discernible health benefit for their target population. These benefits 
materialise through the adoption by public and private sector bodies of the policy insights, 
products, practices or technologies emerging from the research.  
In addition to direct improvements in patient care, the health sector itself can also benefit 
from research findings, for example, through cost savings and quality gains in service RAND Europe  Framing issues 
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provision, and these savings can be re-invested in improved health care provision and 
further research. 
Broader economic benefits 
The scientific, clinical and commercial application of a research project’s findings can 
deliver a wide range of socioeconomic benefits.  
Exploitation of the intellectual property created by research can result in new employment 
opportunities and export potential, and may attract international investment in the 
national research base. The health and health secto r  b e n e f i t s  t h a t  a c c r u e  f r o m  h e a l t h  
research projects contribute to the productivity of a healthy workforce and bring associated 
economic benefits. This type of impact is particularly challenging to measure, due to the 
difficulty of accurately attributing benefits to specific individual research projects. 
It should be borne in m ind that these five “payback categories” may apply in varying 
degrees according to the type of research. For example, when evaluating the outcomes from 
basic science research, it may be the case that knowledge production outputs are more 
common than outputs that inform policy. On the other hand, the outputs from a clinical 
research project might be expected to have a more direct policy influence. Evaluating the 
contribution of basic research to more downstream payback categories, such as policy 
formulation and broader economic benefits, might require, at the very least, a longer 
period of study than a similar evaluation of clinical research. 
2.4.2  The logic model  
The second element of the evaluation framework is the logic model, which describes the 
various stages in the process through which research can generate impacts (Figure 2.1). 
The model does not pretend to be a precise illustration of how research utilisation occurs; 
the processes through which research is translated into actual results are likely to be more 
complex than the model can present. Nevertheless, it provides a useful structure around 
which to organise the assessment of research impact over time and to enable comparisons 
between cases. 
Figure 2-1: The Payback Framework’s logic model of the research funding process 
 
 Source: Hanney et al., 2004 Project Retrosight: Methodology Report  RAND Europe 
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There are seven stages in the logic model, from the initial idea for the research project 
through to the wider impact on society, and each of these is described in detail below. 
Stage 0: Topic/issue identification 
The assessment begins by investigating how the idea for the research was born. There are 
numerous potential sources of the original idea, and in many cases several of these 
contribute to identifying the research topic. They might include: 
•  an individual scientist’s intellectual curiosity; 
•  an existing need (known within the research community) to fill certain gaps in 
scientific knowledge; 
•  a need identified as a result of personal experience (for example, a clinical 
researcher’s personal experience in treating patients); 
•  opportunistic motives, such as availability of funding;  
•  externally solicited research in the form of requests for proposals by a research 
funding body or other interested stakeholder groups.  
Interface A: Project specification and selection 
Different funders exert different degrees of direction with respect to their research funding. 
In pure response mode funding – i.e. when the topic is identified by the research team – 
project specification and selection interface generally involve traditional processes of 
developing a detailed proposal and submitting it for peer review, possibly modifying it 
post-feedback, and then applying for funding (which is either granted or refused). In more 
directed funding, the peer-review process can involve a range of stakeholders and, in some 
cases, a competitive bidding process. 
Stage 1: Inputs into research 
This stage concerns the resources available to the project. These will include financial 
support, human resources (such as scientific expertise and administrative support), physical 
resources (scientific equipment, facilities and general consumables), collaborators and so 
on. 
Some consideration of these inputs by the researchers will already have been required at 
Interface A, when the research proposal and budget requirements were drafted. Now, at 
Stage 1, these requirements may be reviewed and complementary inputs, in addition to 
those budgeted for by the project funding, can be considered. 
These complementary inputs might include the experience and accumulated knowledge-
base of the research team and the availability of equipment and research infrastructure, 
s u c h  a s  u n i v e r s i t y  l a b o r a t o r y  a n d  o f f i c e  s p a c e ,  a d m i n i s t r a t i v e  s u p p o r t  a n d  c o l l a b o r a t o r  
networks that can be tapped into. All these can influence the outputs from the research. 
Stage 2: Process 
Stage 2 evaluates the research process by exploring a number of key issues, including the 
suitability of the research design and methods for answering the central scientific question; 
the difficulties encountered in the research process; factors that facilitate or impede the 
research process; the time and cost efficiency of the research; the nature of collaborations; RAND Europe  Framing issues 
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interactions with potential users of the research as the project is undertaken; and any early 
dissemination of knowledge or adoption activities occurring as findings emerge 
incrementally.  
The sort of factors that can facilitate or impede research may include the level of scientific 
challenge inherent in the programme; general resource availability (human, financial or 
physical); internal team dynamics, which can affect motivation and productivity; relations 
with donors and external collaborators; and levels of flexibility in grant management.  
In some cases, it can be helpful to explore the extent to which collaborators and potential 
users are involved in implementing the research as they can often influence how the 
research evolves.  
Stage 3: Primary outputs from research 
The primary outputs from research fall into the first two payback categories: knowledge 
production and research targeting and capacity building. 
Most knowledge production outputs (publications) will enter the pool of knowledge that 
informs further research, by the same or other research teams, either in the same field or in 
new research areas. They may eventually also become incorporated into policy-making or 
product development processes (see Stage 4, below). If the research helps to secure funding 
for subsequent projects, attracting new recruits or promoting researchers’ careers, it will 
have contributed to building capacity. 
Interface B: Dissemination 
Dissemination is more than just the production of an academic publication containing 
results of the research. A crucial aspect of the translation process is the transfer of research 
findings to potential users in the political, industrial and professional environment and to 
wider society.  
While citations of a published paper can serve as an indicator of dissemination and take-up 
within the academic world, numerous additional activities may also be employed to assist 
in disseminating research findings. These include conference papers and presentations, 
seminars, the production of audience-specific briefs, personal networks for knowledge 
exchange, educational activities, interactions with the media and so on.  
Dissemination is a complex process that takes place over time – during, as well as after, 
completion of the research – and can reach beyond the immediate scientific sector to 
inform other research areas. 
Stage 4: Secondary outputs – policy making and product development 
Secondary outputs contribute mainly to the third payback category: informing policy and 
product development. Unlike primary outputs, secondary outputs can be difficult to 
identify and doing so requires the use of a variety of techniques, including interviews, 
database reviews and bibliometric analyses.  
Evidence of any influence on policy can be found in the form of research citations in 
documents produced by professional and public policy-making bodies. Research findings 
can be used to develop new policy, change policy or maintain an existing policy at all levels 
within an organisation and with varying degrees of impact.  Project Retrosight: Methodology Report  RAND Europe 
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Secondary outputs can influence academic course curricula in medical schools and can be 
cited in patent applications or in the licensing of production rights for drugs, vaccines or 
medical equipment.  
Stage 5: Adoption by practitioners and public 
The adoption by practitioners of the outputs from research is important for their 
translation into widespread health and socioeconomic benefits. Adoption is generally 
accompanied by some sort of change in practitioner or public behaviour. Sometimes 
adoption comes as a direct result of primary outputs, for instance when clinicians decide to 
implement research findings before the development of clinical guidelines. Assessing the 
degree of public adoption of research is more complicated. One indicator is the extent to 
which patient behaviour changes as a result of interactions with those healthcare providers 
who promote research-based messages. Another might be the public response to media 
coverage of research findings. 
When evaluating research outputs, it is important to try to establish adoption or take-up 
rates, and to explore how far a behavioural change can be attributed to the specific research 
findings, as opposed to other factors (such as a more general change in climate of opinion).  
Stage 6: Final outcomes 
The final outcome stage is reached when the broader health and economic benefits of 
research (the fourth and fifth payback categories) become apparent. These benefits can 
accrue over a protracted period of time and are the most difficult to attribute to an 
individual research grant. 
2.5  Unit of analysis 
One of the first decisions we had to make was which specific element of the projects 
making up the sample would be the focus of our study; in other words, what was our unit 
of analysis – the research grant, the scientist, the research programme or the host 
institution?  
We wanted to identify, sample and follow individual pieces of research from inception 
through to the present day; but these needed to be limited enough in scope to allow us to 
construct detailed case studies around them. Our previous experience suggested that using 
research grants as the unit of analysis offered the best compromise. As well as being 
tractable in terms of size and relatively easy to obtain systematic information about, they 
are also of immediate relevance to funders – each grant is not only tied to a specific funder, 
but also to a particular funding decision. Using individual grants as the unit of analysis for 
the project therefore allows our analysis to reflect the choices that funders have to make 
and helps guide the relevance and applicability of the insights generated from the project. 
Grants also have the advantage of being easy to select because lists of grant awards are 
generally kept by the funding bodies that award them. 
One disadvantage of using grants as our unit of analysis was the difficulty of separating the 
work supported by one grant from a group that has multiple, possibly overlapping, grants. 
This issue is discussed in more detail in the section on Case study scope on page 46.  RAND Europe  Framing issues 
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2.6  Selection of time frame 
In choosing an appropriate time window for Project Retrosight we had to balance the need 
to obtain reliable information with the need to allow enough time for the impacts of the 
research to develop. The longer the timescale we selected, the greater the danger that 
records would be missing and recall fading. On the other hand, examining recent research 
projects ran the risk that impacts would not have had a chance to develop. 
Previous studies have suggested that principal investigators’ (PIs’) recollection of their 
research is generally very good, but that the extent of archive records available is heavily 
dependent on the practices of the funders (Wooding et al., 2004; Nason et al., 2008). 
Previously we had successfully carried out research looking back over a 10- to 15-year time 
period (Wooding et al., 2004). In consultation with the steering committee it was decided 
that we would attempt to look back over a 15- to 20-year period, so we selected a start 
point for grants between 1989 and 1993.  
2.7  Selection of characteristics of interest and the selection matrix 
Before embarking on our study we had to select factors that might potentially affect 
research impact and ensure that each was sufficiently represented in our sample. There are 
a great many factors that have been shown to influence research success, or may be 
assumed to do so, and in order to extract findings that could be generalised we needed to 
make sure that we had sufficient numbers to make a comparison along each selected 
dimension. Yin suggests that a useful heuristic for the number of necessary cases is four 
either side of a comparison (Yin, 2003). 
We wanted our research to look not only at the specific factors that we had identified as 
being of particular interest, but also to identify and explore other factors that affect 
research success and describe how these might be influenced. 
There are two types of selection criteria – those that represent dependent variables 
(measures of impact) and those that represent independent variables (things that might 
affect impact). Dependent variables included high and low impact; selecting both ensured 
that we had a variety of outcomes and so could explore what correlated with these. 
Independent variables, such as whether the research was basic biomedical or clinical, 
enabled us to focus on testing a particular hypothesis about whether this factor (which may 
be uncommon) has an effect on impact. 
2.8  Factors used for selecting case studies 
In consultation with Project Retrosight’s steering group, we compiled a list of factors for 
comparative analysis. It included the following.  
•  Country of research (Australia/Canada/UK): selecting a balance of case studies 
across the three countries would allow us to look for national variations arising 
from differences in the research, health systems and cultures of the three countries. Project Retrosight: Methodology Report  RAND Europe 
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•  Type of research (basic biomedical/clinical): grants could be divided into two 
categories – those funding basic biomedical research and those funding clinical 
research. This would be based on the subject of the research grant rather than the 
qualifications of the researcher. 
•  Impact (higher/lower): research grants could be broadly separated into two groups 
– those that had achieved high impact and those whose impact had been low. 
Projects would be categorised based on data on the PIs’ own perception of their 
impact, both academically (e.g. papers) and more widely, in terms of effects on 
health policy and health. This information would be collected through an initial 
PI survey. 
•  Size of grant (large/small): splitting the research grants according to the size of the 
award would permit us to look for differences between large and small grants. 
•  Clinical experience: dividing grants on the basis of whether or not their PIs had 
clinical experience or whether there was a researcher who had clinical experience in 
the team.  
•  Academic age: grants could be divided according to the number of years the PI 
had been active in research. 
•  Age of independence: grants could be divided according to the age at which the 
PI had started his or her own group, rather than carrying out research as part of a 
larger group. 
•  Multidisciplinarity: the range of disciplines in which the researcher, research 
group or grant was active could be used to categorise the case studies. 
•  International collaboration: the level of international collaboration on the grant 
could be used to categorise the case studies. 
•  Soft/core funding: the amount of soft, or discretionary, funding the grant PI 
controlled. There have been earlier indications that having such money allows 
researchers the freedom to pursue their instincts. 
•  Research group culture or PI personality: there is evidence that the personality 
of the PIs and the culture they develop in their research group can affect the wider 
impacts of their work. 
•  Plurality of funding: the number of different funding sources supporting PIs’ 
research. RAND Europe  Framing issues 
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•  Critical mass: dividing researchers by the size of their research groups – or 
possibly the institutions in which they are situated – would allow us to investigate 
the issue of whether scale, or critical mass, affects wider impacts of research. 
•  Institutional setting (university, institute, medical school or hospital): examining 
whether the location of the research group affects its impact. 
•  Curiosity-driven versus mission-directed: dividing research according to how 
much influence funders exerted on the direction of the research – from purely 
curiosity-driven through to directly commissioned research to answer a specific 
question. 
•  Peer-review ranking: dividing research according to how well it was rated in the 
peer-review system for funding application. 
•  Type of research funding: comparing project, programme, fellowship and/or 
institute funding. 
However, the scale of the project (we had settled on a sample of 25–30 case studies) 
suggested that we could focus on only four specific factors for comparative analysis. From 
this long-list we isolated four feasible key factors that would potentially provide insights to 
funding bodies. We selected case studies that would balance the following factors.  
•  Impact of research – in order to get an immediate measure of the impact of each 
research grant, we aimed to select a sample that contained both high- and low-
impact research. This would allow us to support our conclusions by demonstrating 
the presence of certain features in high-impact research and their absence in lower-
impact research. 
•  Type of research – this allowed us to examine the relative levels and types of 
impact of basic biomedical and clinical research, something that was also a key 
interest of the steering committee. 
•  Country of research – Project Retrosight gave us an opportunity to examine 
whether or not national context plays a key role in research outcomes. 
•  Size of research grant – we wanted to try and understand how different sizes of 
grant were used and the relative benefits that each brought.
4 
To reduce the variety of other factors we needed to consider we decided to focus on just 
one mode of funding: project/activity grants. This was largely because we needed a funding 
type that was broadly similar, and therefore comparable, in all three countries. We have 
                                                       
4 In later analysis this proved problematic as the range of sizes was relatively small, differed between countries 
and was not always correctly reported in funders’ records. For these reasons we have not attempted any analysis 
based on grant size. Project Retrosight: Methodology Report  RAND Europe 
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examined funding type as a factor affecting research impact in an earlier study using the 
Payback Framework (Wooding et al., 2005). 
2.9  The selection matrix 
These four key characteristics allowed us to construct a selection matrix showing the 
variety of case studies that we wanted to select (Figure 2.2). Ideally, we were aiming for at 
least one case study in each cell of the matrix in each country. An initial error in data 
extraction from the survey led to the misclassification of some grants, but because some of 
these case studies had been started by the time the error was corrected they were kept in 
the sample. This had a small effect on the distribution of cases across the matrix. Six PIs 
declined to participate in the study; in one case we could not find sufficient data to 
complete a case study; in another initial scoping revealed the research did not meet our 
inclusion criteria; and in one instance the PI had moved to Japan. Some of the studies 
affected could not be replaced due to time and budget constraints. 
 
Figure 2-2: Selection matrix  
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CHAPTER 3  Identifying candidates for case studies 
3.1  Introduction 
In this chapter we describe in more detail how we identified the grants that would form 
the subject of our case studies. Essentially, this process consisted of consulting the records 
of funders to identify relevant grants; establishing whether the PIs of these grants had 
published between 2004 and 2006; locating contact details for the PI; surveying the PIs to 
collect more information about them and their projects; and then using all this 
information to assign the grants to one of the cells of the selection matrix. 
3.2  Grant identification 
The selection process began with the identification of grants awarded in the cardiovascular 
and cerebrovascular research field between 1989 and 1993 by various funders, including 
the British Heart Foundation (BHF) and the Stroke Association in the UK, the Heart and 
S t r o k e  F o u n d a t i o n  ( H S F C )  a n d  C a n a d i a n  I n s t i t u t e s  o f  H e a l t h  R e s e a r c h  ( C I H R )  i n  
Canada and the National Heart Foundation (NHF) of Australia. All of these organisations 
were able to provide lists of grants awarded during the project time period. The National 
Institute for Health Research (NIHR) had no such centralised lists for its funding from the 
early 1990s because most of its funding was administered locally at that time, and so we 
were unable to select grants supported by NIHR. Had we needed to extend the range of 
grants from which to select our case studies, we might have consulted other organisations 
in the study countries that were funding research in the cardiovascular field during the 
relevant time period (these included the Medical Research Council and the Wellcome 
Trust in the UK and National Health and Medical Research Council in Australia). 
However, given the other sources of funding held by our case study PIs we are confident 
that our case studies cover the range of research in cardiovascular disease and stroke at the 
time, as well as a sample this size can. 
We assumed that all grants from the BHF, Stroke Association, HSFC and NHF would be 
within the scope of the project. In addition we added grants from the CIHR that were 
considered to be in the field of cardiovascular and stroke research. If the CIHR research 
team considered the grant title to be relevant, a checking process aided by both CIHR’s 
own funding data and information on projects co-funded by HSFC, the project was 
deemed to come within the scope of Project Retrosight. Project Retrosight: Methodology Report  RAND Europe 
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3.3  PI survey 
The funder records did not contain enough information for us to assign the grants we had 
identified to cells in the selection matrix (particularly for categorising by research type), so 
we decided to collect the extra information by carrying out an online survey of the PIs.  
Broadly speaking, the survey content was the same for all three countries, although we 
made some minor adjustments to the language and terminology to take account of 
particular characteristics of the research system in each. We also provided a French 
translation of the survey in Canada. 
3.3.1  Survey outline 
At this early stage we were relying on the willingness of the PIs to get involved with the 
project. To maximise response rate and avoid burdening PIs, it was crucial that we kept the 
survey concise. 
The survey had three sections: the first asked for basic information about the PIs, including 
their gender and the number of years, post-doc, they had been working in research. The 
second and third sections asked about grants awarded to the PI in the period 1989–93. If 
the PI had received more than one grant, the second and third sections were repeated for 
the first two grants awarded. We did not ask about more than two grants to minimise the 
time needed to complete the survey and (we hoped) increase the response rate. 
The second section focused on the nature of the grant itself, including whether it was 
concerned with basic biomedical or clinical research and whether it was interdisciplinary in 
focus. We had initially hoped to be able to separate the basic biomedical research grants 
from the clinical ones using only funders’ records; unfortunately, we found that each of 
our funders had a slightly different way of distinguishing between the two. Because of this 
we asked the PIs to classify their research according to the following hybrid of our funders’ 
definitions: 
•  basic biomedical – focuses on normal or abnormal function at the molecular, 
cellular, organ or whole body level; 
•  clinical – focuses on patients, better diagnostics or treatments and increasing 
quality of life. 
The third section of the survey asked about PIs’ perceptions of the impact of their research 
projects. This included information about the number of publications directly attributable 
to the grant, whether or not the research had led to further work by them or others, 
whether any post-graduate degrees were attributable to the grant, the scale of the project’s 
impact on policy, whether or not the research had led to product development and an 
assessment of the project’s impact on clinical practice. 
The survey was designed as a simple tick-list that would take no more than ten minutes to 
complete. Most questions required a “yes/no” answer while questions such as the extent of 
impact on clinical practice were answered using a three-point scale (Appendix A gives the 
full survey). These techniques made it easy for PIs to complete the survey and easy for us to 
add up the overall perceived impact of the grant. RAND Europe  Identifying candidates for case studies 
19 
3.3.2  Building the survey tool 
As our survey sample was spread over three countries, we felt the most efficient way of 
conducting the survey would be online. Because of the highly specific nature of the data 
collection, and the fact that only a small number of coded answers were required, we built 
our own online tool to collect the survey responses. This had the added benefit of further 
reducing the administrative effort required to complete the survey by the PIs, since each 
individual could be sent a unique URL. 
3.3.3  Testing the survey tool 
Before using the survey, we conducted preliminary tests with PIs in each of the 
participating countries and requested feedback. The response was generally favourable, but 
at the same time some significant criticisms were made that enabled us to fine-tune the 
content and structure of the survey. 
Some of the test respondents believed that the survey was the main method of data 
collection for the whole project. We responded by inserting a line in the survey 
introduction to explain why the information was being collected and that the focus of the 
research would be detailed case studies of the grants in question. 
It later transpired that our test-run failed to test the data extraction from the survey 
sufficiently, with the result that some grants ended up wrongly classified in the initial 
selection matrix. We were able to correct this mistake subsequently but it did mean that 
some case studies that had already been started had to be reclassified. This contributed to 
some slight imbalances in the final case study matrix.  
3.3.4  Survey deployment and response rates 
To carry out the survey we had to obtain current email addresses for all the PIs. For 
Canada and Australia the funders were able to provide us with relatively complete, up-to-
date email lists (covering 80% and 99% of PIs in our time window respectively). However, 
in the UK such lists were not available and we had to hand-search for email addresses, 
identifying them for 47% of UK PIs. To focus our search effort, we excluded PIs who had 
not published between 2004 and 2006. To identify PIs’ publications we searched the 
Thompson Reuters Web of Science databases using the researcher’s surname and first initial. 
We used only one initial, which increases the chances of including some papers in fact not 
by the PIs, because we wanted to err on the side of inclusion rather than exclusion. This 
filter excluded 21% of the PIs initially identified. Table 3.1 gives more details on the 
number of email addresses and bibliometrically active PIs. 
 
Table 3-1: The number of PIs, email addresses and level of bibliometric activity 
  Australia Canada  UK 
Number of PIs identified from funder lists 222 572  553 
Number of PIs for whom we had email address 220 457  261 
Number of bibliometrically active PIs – published in 
2004–6 
180 427  451 
Percentage of identified PIs bibliometrically active 81% 75%  82% Project Retrosight: Methodology Report  RAND Europe 
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3.3.5  Identifying email addresses 
We located email addresses for the bibliometrically active researchers from funder records 
and through the PubMed online database and Google searches. We then surveyed these 
PIs to find more details about them and about the grant. Some PIs had been awarded 
several grants during the time period specified, but we asked them to provide answers for 
no more than two in order to keep the survey concise. The average response rate to the 
survey, in terms of grants, was 33% and was similar across countries (see Table 3.2). This 
raises the possibility that some difference between responders and non-responders may 
have biased our sample. In particular, it might be expected that those researchers who 
perceived their projects as having a greater impact would be more likely to respond. Our 
deliberate selection of both high- and low-impact research should mitigate this possibility 
to a large extent, but it is nonetheless a caveat to bear in mind when considering the place 
of our case study grants in the wider research context. 
 
Table 3-2: The number of PIs contacted and the number who responded in each country 
  Australia Canada UK 
Number of PIs surveyed 220 457 261 
Number of responses 72 158 78 
Response rate  33% 35% 30% 
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CHAPTER 4  Case study selection 
4.1  Filling the matrix 
Having decided on the time window, selected our key characteristics, identified relevant 
cardiovascular and stroke research grants awarded during that period and collected the 
necessary additional information on each grant through the PI survey, we then had to 
make our final selection of grants to investigate in case studies. 
To do this, we allocated each grant to a cell of the selection matrix thus. 
•  Country: allocated according to the country in which the research was carried 
out, even if the researcher had subsequently moved countries. 
•  Type of research: allocated to clinical or basic biomedical according to the PI’s 
survey response. 
•  Impact of research: calculated from the PI’s survey response by simply totalling 
the responses in the impact section of the questionnaire. We plotted the 
distribution of impact across all grants (separately for basic biomedical and clinical 
research) and then cut these distributions in half to produce higher impact (top 
half) and lower impact (bottom half).  
•  Size of research grant: from funder records. We removed the extreme outliers 
and then split the distribution in two, considering the top half “larger grants” and 
the bottom half “smaller grants”. 
From the data collected in the survey we were able to populate our case study selection 
matrix (see Table 4.1) 
 
Table 4-1: Number of grants we received survey responses on in each cell of the selection matrix 
  Canada  Australia  UK 
Basic biomedical 
Higher impact  71  Higher impact  27  Higher impact  21 
Lower impact  60  Lower impact  28  Lower impact  24 
Clinical 
Higher impact  7  Higher impact  5  Higher impact  7 
Lower impact  14  Lower impact  5  Lower impact  8 Project Retrosight: Methodology Report  RAND Europe 
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4.2  Selecting the cases 
Having generated a list of grants for each cell in the matrix we then worked through the 
cells, country by country, randomly selecting (by coin-tossing) which grant to use for the 
case study. 
Analysis of our survey results showed that 25% of the responding researchers were women. 
We therefore tried to select so that 25% of the case studies had female PIs to ensure there 
was no ri sk of ge nde r bias . We  did th is by working from  c ountry to country a nd, if  
necessary, selecting randomly from just the women or men in a particular cell. 
In Australia and Canada we were asked to select a geographical distribution of case studies. 
We did this by monitoring the emerging selection and, when necessary, selecting from 
only the case studies in under-represented geographical regions from particular cells. 
We then approached PIs to participate in the study. In instances where PIs declined to 
participate in the research or were otherwise excluded, we returned to the cell in the matrix 
and selected randomly from the remaining case grants. PIs were excluded from the research 
if they had moved from the initial country of the research to a country outside the study 
(this happened in one instance). There were no examples of PIs moving from one of the 
countries participating in the study to another after their case study grant, although some 
had moved between participating countries before the period surveyed.  
We had agreed to exclude PIs who were in legal dispute with any of the funders, but there 
were no instances of this in our selection.   
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CHAPTER 5  Case study research 
5.1  Pilot case study 
Before embarking on the study we conducted a pilot case study to test our methodology. 
In a previous study for the Arthritis Research Campaign (Wooding et al., 2004) we 
undertook an initial round of case study pilots and reported these to our steering 
committee before proceeding with the subsequent 13 case studies. These initial studies 
were valuable in demonstrating the applicability of the Payback Framework to early clinical 
and basic biomedical research and also provided methodological refinements, for example 
highlighting the importance of interviewing the PI early in the process, before extensive 
review of subject-specific documentation.  
Although our previous work gave us confidence that the same approach would work for 
Project Retrosight, we wanted to confirm our belief that the Framework was applicable to 
cardiovascular and stroke research. Therefore we conducted a single pilot case study in the 
UK and used the results, along with an explanatory research pack, to illustrate the 
approach to the study teams in Canada and Australia.  
While we did not consider it necessary for the other participant countries (Canada and 
Australia) to conduct additional pilots, we staggered the start of the case studies to allow 
early feedback and to give ourselves time to make any necessary adjustments. The case 
studies were therefore separated into two tranches that began successively rather than 
simultaneously. 
Selection of the pilot case study was largely pragmatic because we wanted to study a 
researcher whose work was likely to have had some impact and who was easy for us to visit. 
We began the pilot exercise by approaching specialists in the field of cardiovascular 
medicine to get an idea of the current trends in cardiovascular and stroke research. We 
then sought a suitable candidate to approach for our pilot study.  
We selected a project run by a senior cardiologist based in Cambridge. The PI was an 
influential figure in the field of cardiovascular medicine, who had a reputation for 
producing high-impact research.  
The case was a British Heart Foundation fellowship dating from 1990 and the PI was a 
practising cardiologist who had been encouraged to apply for the fellowship by a BHF 
researcher.  Project Retrosight: Methodology Report  RAND Europe 
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Having identified the pilot case we applied the framework and looked at the project inputs 
(money, knowledge, expertise, space, consumables and so on) and its outputs, including 
dissemination and final outcomes.  
This pilot case study not only demonstrated the suitability of our chosen methodology but 
also provided us with a better understanding of how we should perform the actual case 
studies for Project Retrosight. It focused our attention on issues such as how to attribute 
research outputs to a grant, how to define an outcome, what constitutes adoption and 
what should be included as a “wider” outcome. 
5.2  Cross-country working 
The case study work for Project Retrosight combined several distinct research methods 
(described on page 25) and was carried out by teams of researchers in each country, 
coordinated by the UK team.  
The Australian research was conducted by an internal staff member of the NHF of 
Australia and by market research specialists Instinct and Reason. In Canada, the research 
was carried out internally by staff at the CIHR. The UK team from RAND Europe and 
HERG conducted all UK research as well as coordinating the research carried out in 
Australia and Canada. 
We took a number of steps to develop a consistent approach across the teams, including 
providing written protocols and templates and running a series of three workshops during 
the course of the project. The protocols are included as appendices to this report and the 
content of the workshops is described below. The workshops served as opportunities for 
the Canadian and Australian researchers to familiarise themselves with the Payback 
Framework and methods used in the study, and to review initial findings with the 
RAND/HERG researchers. 
Workshop 1: Santa Monica, February 2007 
•  Familiarisation with different countries’ funding systems 
•  Introduction of the Payback Framework; presentation of pilot case study 
•  Discussion of process and data requirements for case study selection 
•  Discussion of project outline 
Workshop 2: Santa Monica, December 2007 
•  Review of selection survey responses 
•  Review and discussion of initial case study work 
•  Review of case study templates 
•  Discussion of classification of narrative, outputs and outcomes into the Payback 
Framework RAND Europe                                                                                                             Case study research 
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Workshop 3: Cambridge, June 2008 
•  Review of later stages of research for initial tranche of case studies and initial 
research on further case studies 
•  Further discussion of classification of narrative, outputs and outcomes into the 
Payback Framework 
•  Review of challenges and issues arising from data collection and case study write-
ups 
•  Presentation of initial bibliometric analysis for case studies 
•  Discussion of structure of analysis phase 
5.3  Case study research methods 
Each case study combined data from a variety of sources including archival documents and 
published literature, bibliometric information and semi-structured interviews with PIs and 
other informants. In this section we look in detail at how the case study research was 
carried out. 
A range of background material was reviewed before conducting interviews for the grants 
selected, and this was referred to throughout the case study research process. 
5.3.1  Document and literature review 
We undertook a review of a range of materials – original grant applications, referees’ 
reports and other relevant documentation (including subsequent correspondence between 
applicants and funding bodies) – to gather information about the grant and the PI. We 
also reviewed interim and end-of-grant reports if they were available.  
In addition, we skimmed the peer-reviewed papers and reports that had been produced by 
the PI at around the time of the grant. These documents were located through searches in 
Thompson Reuters Web of Science databases and Google Scholar. After we had carried out 
the PI interview we then reviewed in detail papers the PI considered to have arisen from 
the grant. 
The pilot case study demonstrated that even if the funder had disposed of grant records, 
the PIs or their institutions may have retained copies of such documents.  
5.3.2  Interviews 
After our background research we conducted semi-structured interviews with the PI for 
each grant. Through these interviews we identified others who had also been involved in 
the research (clinicians, collaborators and other stakeholders), and they were approached 
for interview as well. Conducting multiple interviews enabled us to obtain several 
perspectives on the issues we were investigating and gave us enhanced insight into 
individual experiences. Different interview protocols were employed for PI and non-PI 
interviews (see Appendices B and C). Project Retrosight: Methodology Report  RAND Europe 
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The interviews were modelled on the Payback Framework and explored the origins of the 
research, the primary outputs and any translation of research findings into product 
development, policy or practice. 
Most interviews were conducted face-to-face, with a few by telephone. Each interview 
lasted between 60 and 150 minutes. In addition, interviews were often followed up with 
email correspondence and telephone enquiries and clarifications. Interviews were recorded 
and the recordings preserved for later reference. All recordings were held in accordance 
with the retention and data protection policies of the organisation leading the case study. 
The interviews began with an introduction to the payback model in the evaluation 
framework and an explanation of the aims of the study. The interview protocol followed 
the structure of the model itself. We explained to the interviewees that not all the questions 
would be relevant to their research project. The interviewers, during their desk research, 
had the opportunity to introduce additional questions and these were added to the basic 
interview protocol.  
Non-PI interviews also closely followed the payback model but differed from the PI 
interviews in that they reflected the informant’s involvement in the project. Non-PI 
interviews were often more focused than PI interviews, concentrating on a specific area of 
the research or dissemination. For example, if informants were only involved in 
dissemination, they were not asked about the early stages of the project. 
5.3.3  Bibliometric analysis 
Bibliometrics is the use of publication and citation data to assess the research performance 
of individuals, groups and institutions. We used this method to assess the significance of 
the papers produced from our case studies. To do this we identified the papers directly and 
indirectly linked to the case study grant and analysed the citations that they had received. 
This required us to carry out two key steps: first, identifying the relevant papers and 
second, capturing the citations of those papers. 
On occasion we also used bibliometrics to trace the impact of case study research by 
approaching authors who had cited the papers to ask how it had affected their research. 
Identifying the papers 
Initially we identified lists of publications for all PIs from the year in which their research 
grant started to the present day. Details were extracted either from the PI’s CV or from the 
Thompson Reuters Web of Science (WoS), which includes author lists, article titles, 
publication names, volume and issue numbers, page numbers and finally ISI (Institute for 
Science Information) numbers in each case.  
We showed this list to PIs during the interviews and asked them which papers could be 
attributed to the case study grant. We asked them to classify related papers into two 
groups:  
•  directly related – papers that arose directly from the research conducted on the 
grant in question; RAND Europe                                                                                                             Case study research 
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•  indirectly related – papers to which the research on the grant in question made a 
substantial contribution, and to which other research grants held by the PI may 
also have contributed. 
We also asked the PIs to add other publications (such as abstracts and poster presentations) 
that were not in the WoS database or noted on their CV. 
In some cases there was confusion over definitions. For example, in a few instances the 
number of papers the PI claimed were related to the grant was so large that it raised doubts 
about the legitimacy of the claim. In others, the PI and non-PI interviewees disagreed 
about the attribution of particular papers. 
For instances where there was confusion over the attribution of papers, we developed a set 
of guidelines to help the Project Retrosight case study research teams identify whether 
papers should be regarded as attributable, directly or indirectly, to the grant in question 
(see Figure 5.1). 
 
Figure 5-1: Guidelines for paper attribution 
 
 
Final paper lists were reviewed by the country teams to ensure they were accurate and the 
list of papers classified as directly attributable was analysed. Although some discrepancies 
remained, it is important to view these in context: the bibliometric analysis provided only 
We provided the following guidelines to help case study researchers decide 
whether or not papers were attributable to the grant in question: 
1.  Does the paper acknowledge the specific grant (e.g. through a grant 
number)? 
2.  Does the paper acknowledge funding from a body other than the 
grant funder? 
3.  Is there common authorship between the grant applicant (PI, co-PI 
or other named investigator) and the paper? 
4.  Is there common keyword or title use between the grant application 
and the paper? 
5.  Is there common content between the grant application and the 
paper? 
If the answer to question 1 was “yes”, the paper was attributable to the 
grant. 
If the answer to question 2 was “yes”, the paper was not attributable.  
If the answers to questions 3, 4 and 5 were “yes”, the paper was attributable Project Retrosight: Methodology Report  RAND Europe 
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one strand of evidence for the level of knowledge production, which was itself only one 
strand of data for the final analysis. 
 
Analysing the publications list 
The extraction of bibliometric data used in Project Retrosight was undertaken by the 
Centre for Science and Technology Studies (CWTS) and the data were analysed by the 
Research Evaluation and Policy Project (REPP) at the Australian National University. 
The bibliometric data detailed in Figure 5.2 were extracted by CWTS to assist in assessing 
the knowledge production of each of the case study grants. The data were presented in the 
form of a one-page summary for each case study. Once the paper lists had been compiled 
and agreed, the papers were identified in the CWTS database and their citations analysed. 
Details of the analysis methods are given in Figure 5.2, followed by descriptions of the 
indicators computed. RAND Europe                                                                                                             Case study research 
29 
Figure 5-2: Details of analysis methods and indicators used 
Analysis methods 
Database used 
The Centre for Science and Technology Studies (CWTS) at the University of Leiden 
bibliometric database, which is based on the Thomson Reuters Web of Science (WoS) 
database. 
Period covered 
1981–2007 for the overview analysis; year of publication to 2007 for grant-related 
publications. 
Counting method 
Whole counting, i.e. a full publication and citation count was allocated to grant 
outputs even when the publication was co-authored with researchers outside the study 
group. 
Publications covered 
The analysis included all research and review articles, notes and proceedings papers in 
journals indexed in WoS. Letters to the editor, editorials, and the like were not 
included, and articles in journals not indexed by WoS were also excluded from citation 
analyses. 
Indicators 
Number of journal articles 
Total number of journal articles directly related to the case study research project. 
Number of articles indexed by WoS 
The number of these articles appearing in journals indexed by Thomson Reuters in the 
WoS database. 
Total number of citations (all papers) 
The number of citations received by these (WoS-indexed) articles from the year of 
publication to the end of 2007. 
Aggregate relative citation impact  
The average citation per publication rate for the grant outputs was compared to the 
citation per publication rate for all cardiovascular/stroke publications, calculating a 
relative citation impact (RCI). This overall RCI was then sorted into one of five classes: 
Class I  uncited 
Class II  > 0 but < 0.8 
Class III  0.8 to 1.2 
Class IV  1.2 to 2.0 
Class V  > 2.0 
Self-citations 
Self-citation was defined as the proportion of citations received by the grant-related 
publications that came from other publications written by one or more of the same 
authors. Although self-citations were included in citation counts, the extent of their 
contribution to the total citation count was calculated and indicated in the case studies. Project Retrosight: Methodology Report  RAND Europe 
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Distribution of publications across relative citation impact classes 
Each publication derived from the grant was assessed against the cardiovascular/stroke 
citation per publication rate for the relevant year, and assigned an RCI class. The 
publications were then distributed across the five classes in tabular form. 
The most highly cited publication in each case study was identified, and final citation 
counts were extracted for these in April 2009. 
Fields of research of output 
The publications related to each grant were classified, on the basis of the journals in 
which they appeared, in one or more of the WoS subject categories. The data were then 
presented in the form of a pie chart. 
Fields of citing papers 
All articles that cite the publications related to a grant were classified, on the basis of 
the journals in which they appeared, in one or more of the WoS subject categories. In 
the WoS classification scheme, some journals are classified in more than one field. 
Where this occurred, the count for the article was fractionated across the fields. The 
data were then presented in the form of a pie chart. 
Countries of citing papers 
Data on the countries of the citing articles (determined from the addresses attached to 
the articles) were collated. Where authors from two or more countries collaborated on 
one of the citing papers, the count for the article was fractionated across the fields.  
5.4  Case study write-up and review 
The different types of information collected for each case study were written up using a 
standard template structured around the Payback Framework. The three international 
workshops, held during the write-up of the first tranche of case studies, helped to 
standardise our reporting and allowed us to refine the templates. 
To improve consistency between countries further, two members of the RAND/HERG 
team reviewed all the initial drafts of the case studies and provided feedback on tone, areas 
for further examination, and inclusion and exclusion criteria for impacts and outcomes. 
The case studies were then completed by the case study research teams. Once each case 
study had been drafted it was circulated to the PI for clearance. 
5.5  External review 
The case studies depended heavily on information from the PIs and other informants 
involved in the research projects, much of which could be checked against documentary 
sources. But in order to ensure reliability we also sought independent external peer review. 
For each case study we identified other experts in the subject area and asked them to 
review the case studies for historical accuracy. These reviews were used in assuring the 
quality of the case studies and informing the subsequent impact rating process (described 
below). RAND Europe                                                                                                             Case study research 
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Our ideal was to recruit two reviewers for each case study, one from the same country as 
the PI and one from one of the other two countries taking part in the study. We managed 
to achieve this for 24 of the 29 case studies but, despite approaching over 200 reviewers in 
total, we managed to secure only one reviewer for each of the five remaining case studies 
(one in Australia, one in Canada, three in the UK).  
We identified potential reviewers in a number of ways: journal editorial boards, scientific 
advisory boards of medical charities and research funders, authors of highly cited reviews in 
the relevant field, and senior researchers in high-profile research institutes or university 
departments. We focused on senior people, because of their expertise and respected 
position, and also because junior researchers were unlikely to have been actively involved in 
the field during the case study period. If they agreed to participate, we sent reviewers the 
draft case study and asked them to comment on the accuracy of both the impacts 
attributed and the science described, as well as whether the influence of others in the field 
had been sufficiently acknowledged. The instructions and review form provided to 
reviewers are included in Appendix D. 
The verdict of the majority of reviewers was that the case studies were a reasonable 
summary of the scientific history and the role played by the case study PI. In only one 
instance did we receive dramatically conflicting reviews; for this case study we sought a 
third opinion to clarify the situation. Summary tables and the full text of the reviews were 
used during the analysis, described in the following section.   
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CHAPTER 6  Rating impact 
The questionnaire we circulated to PIs provided an initial subjective measure of the impact 
of their research; but after completion of the case studies we had far more information, 
from a variety of sources, on which to base this assessment. In this section we describe in 
detail the process we used to rate the case studies, including how we assembled and 
deployed the rating panel, through to the rating scale we used and how we carried out the 
rating process. 
Inevitably, each grant had achieved different levels of impact in each of the five categories 
of the payback model. So as well as assessing the overall impact and value for money of 
each grant, we also wanted to assess the level of impact for each in each individual payback 
category. 
Each member of our rating panel was asked to produce a series of ratings for each case 
study, covering the five payback categories (knowledge production, research targeting and 
capacity building, informing policy and product development, health and health sector 
benefits, broader economic benefits) plus overall impact and value for money. 
6.1  The rating panel 
The panel was made up of both researchers familiar with the project and others new to it, 
who were invited to provide a degree of external validation. It included a case study 
researcher and an external expert on biomedical research funding from each project 
country, as well as one expert from a country not included in the project to provide an 
entirely independent perspective. The full membership of the panel is shown in Table 6.1. 
 
Table 6-1: Rating panel membership 
  Expertise
Jonathan Grant Study co-principal investigator and methodology expert 
Martin Buxton Study co-principal investigator and methodology expert 
Stephen Hanney UK case study researcher and methodology expert 
Rob Mercer Australian case study researcher
Laura McAuley Canadian case study researcher and expert on Canadian 
biomedical research funding system 
Liz  Allen  Methodology expert and expert on UK biomedical research 
funding system Project Retrosight: Methodology Report  RAND Europe 
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Marcus Nichol  Expert on Australian biomedical research funding system 
Cy Frank  Expert on Canadian biomedical research funding system and 
methodology expert 
Brendan  Curran  Expert on Irish biomedical research funding system and 
methodology expert 
 
6.2  Rating scale 
In order to reduce each case study to a set of ratings for each of the five payback categories, 
for overall impact, and for value-for-money, we devised a rating system based on a scale 
from 0–9: 
0 = no impact in this category 
9 = the case study (or studies) in the complete set with the most impact in the 
category 
1 = the case study (or studies) in the complete set with the least impact in the 
category 
The remaining case studies were given ratings between 0 and 9 based on their relative 
impact in the category. Multiple case studies could receive the same rating (so, for 
example, more than one case study could be rated 4 in any given category). Similarly, there 
could also be gaps in the 0–9 scale (there may be no case study rating 6, for example). 
This scale was derived from the RAND/UCLA appropriateness method (Fitch et al., 
2001), previously used for our work on arthritis research, with the addition of 0 for no 
impact. 
The system had a number of advantages. First, the scale was both discriminating and 
manageable: the 0–9 scale provides a reasonably sensitive measure compared to, say, a 0–3 
scale, but is easier to apply than a ranking of all 29 case studies.  
Second, the rating system ensured the use of the entire 0–9 scale. Raters were required to 
use the whole scale, rating at least one case study 0 or 1 (for no impact or least impact) and 
at least one 9 (for most impact). Had we not done this, the ratings could have been 
distorted by subjective judgements; for example, a rater might consider that none of the 
cases was worth a 9 so the range of ratings used would be narrowed.  
By reserving the value of 0 for no impact we ensured that all the case studies with impact 
were spread over the entire range of the scale (1–9), rather than allowing each rater to 
decide what the case study with the least impact above 0 was worth (in such instances, one 
person’s 2 may be another’s 5). This did have a disadvantage, in that it meant that the 
range of the rating scales in different categories were not comparable. For example, a 9 in 
one category did not necessarily represent as great an impact as the same rating in another 
category. However, judgements regarding the relative value of impacts in different 
categories, which are by definition qualitatively different, would be a highly subjective 
exercise, and we felt that there was greater value in obtaining a more fine-grained analysis 
within each category by spreading the ratings out on each scale as much as possible. RAND Europe                                                                                                                      Rating impact 
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Our rating system also facilitated the presentation of agreement and disagreement among 
the raters. The scale allowed us to draw a simple histogram to show how well ratings 
agreed and to quantify this relatively simply by measuring the mean deviation from the 
median – that is, the average of how far each person’s rating was from the median rating 
(the calculation of this is discussed further in section 6.5). Such a process would also allow 
us, if necessary, to moderate the ratings of individual raters. Comparing the behaviour of 
individual members of the rating panel, by plotting the distributions of their ratings 
(overall or by category), allowed us to see if some were consistently more conservative or 
more generous than others. 
The rating scale also ensured independence of ratings. Members of the rating panel could 
change the rating of one case study in a category without affecting their ratings for other 
case studies. Had we used a system of rankings, moving one case from 2 to 8 would have 
affected the rankings of all the case studies in between. 
6.3  Rating material 
The panel was provided with summary material prepared from the case studies but they 
also had access to the full case studies and peer review comments in case they wished to 
refer to them for more detailed information.  
The set of summary material included the following.  
Payback table 
This summarised the key outputs for each case study under each of the five payback 
categories. Raters reported that this table was the primary tool used in the rating process. 
A case study summary table 
This table summarised the case study narratives organised by stage of the research process. 
Each section could be cross-referenced back to the full case study text and, as well as 
providing additional background material, gave a fuller explanation of the context than the 
payback table. 
Bibliometrics data 
These were presented as a series of charts showing the number of papers attributed to the 
grant, the number of citations they had received and how these citations were distributed. 
Impact matrix 
This was a graphical representation of the impacts of the grant covering the two payback 
categories research targeting & capacity building and informing policy & product 
development, presented as a matrix. The representation was a simplification of the RAISS 
impact array representation and was completed by the case study authors (see Wooding et 
al., 2009 for further details on the RAISS impact array). 
Peer review summary table 
This table summarised the comments received from peer reviewers on the accuracy and 
clarity of each case study, with particular focus on comments about the level of impact and 
degree of leadership in the field. Project Retrosight: Methodology Report  RAND Europe 
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6.4  Rating process 
The panel was then asked to complete the rating process over a two week period in 
advance of the February 2010 rating workshop, where the process – and some specific 
rating decisions – were discussed. The main aims of bringing the rating panel together 
were to ensure we had a common understanding of the rating process and to give us the 
opportunity to re-rate some of the case studies in respect of any improvements in 
understanding that came about through discussion at the workshop. No efforts were made 
to reach consensus scores; the re-rating simply allowed raters to consider information heard 
at the workshop and integrate it into their ratings. 
The aim of the rating process was to define groups of high-, mid- and low-impact case 
studies in which we could identify and test factors that may be associated with impact. As 
such, the precise scores themselves were not critical; what was important was the position 
of each case study relative to the others within each category. High- and low-impact groups 
could then be compared to a series of binary variables representing the presence or absence 
of each factor in each case study. Grouping case studies in this way and focusing on the 
two extreme subgroups meant that we did not use all the data at the initial stage of 
analysis. However, this is a well-established technique in scale development, and division 
into three groups to conduct such analysis is in line with the standard method for 
computing classical discrimination indices (e.g. Crocker & Algina, 1986). Computing 
point-biserial correlations, or non-parametric equivalents, on the entire data set would have 
been less feasible given the small number of cases involved, and may have given the 
impression that our rating figures had an unwarranted level of accuracy. Further detail on 
how the impact categories and groups were derived is provided in Chapter 8. 
6.5  Initial rating 
Each panel member was provided with an instruction sheet (see Appendix E), the set of 
summary material and a scoring sheet, and asked to rate all 29 case studies in each of the 
seven categories. All members completed their rating according to the instructions and 
prior to the workshop. 
In order to assess the rating process and prioritise which case studies to discuss at the rating 
workshop, we measured the degree of disagreement between raters. This was done by 
taking each payback category in turn and, for each case study, calculating the deviation 
from the median for each rating and averaging them. We termed this measure the Average 
Deviation from the Median (ADM). It is similar to the inter-rater reliability measure 
Cronbach’s Alpha, which is based on the mean, but we chose to use the median because it 
is less sensitive to extreme values and shape of distribution. In addition to its neutrality to 
the latter, it is also intuitively appealing and easy to understand from a rater’s point of 
view. It is calculated as follows: 
 RAND Europe                                                                                                                      Rating impact 
37 
We used these case study/category ADMs to help us decide which case studies to discuss in 
each category at the rating workshop.  
6.6  Workshop 
At the workshop we worked through the ratings category by category, discussing the cases 
in which there was most disagreement. The aim of the workshop was not to alter the 
opinions of any of the panel members or to produce consensus, but to reduce differences 
in understanding of the projects or impact terminology while preserving genuine 
differences in subjective valuation of the impacts.  
Each member of the rating panel was given histograms showing where their rating fell in 
the overall distribution of ratings but not revealing who had produced any of the other 
ratings, as shown in Figure 6.1. 
 
Figure 6-1: Illustrative section of rating sheet 
 
 
This system was designed so that no individual member of the panel was singled out as 
having rated differently from the rest. We did this to avoid forcing a consensus because we 
wanted to preserve differences in valuation. 
Time constraints meant we could not discuss every rating so we concentrated on those 
ratings where there was the highest level of disagreement or where raters had expressed a 
particular desire to discuss a certain case study. 
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CHAPTER 7  Data characterisation and robustness 
testing 
Before moving on to our detailed analysis we wanted to understand the data we had 
produced and explore potential biases in our analysis. 
In any project like this there will be biases and weaknesses in the data set. In this section 
we review the tests we did to reassure ourselves about the robustness of our data, examine 
the features that might have confounded our observations and explain how we dealt with 
them. We examined various features of our data, starting with the characteristics of the 
case study sample, and then looked at the rating process to check whether our panel 
members were behaving similarly. Finally, we examined characteristics of the case studies 
that we thought might confound our analysis, looking at the scope, basic biomedical/ 
clinical definition, and presence of negative or null findings. 
7.1  Potential sample bias 
As discussed previously in Chapter 3, there may have been some unavoidable bias in the 
response to our PI survey. In addition to this, we identified two other ways in which our 
selection methodology could have created bias in our final case study sample. 
First, in relying on a bibliometric filter to focus our search for PIs, we are likely to have 
biased our sample in favour of younger PIs and those who remained in research. This 
could have led to more successful grants being overrepresented in our sample, as 
researchers who are successful are more likely to have stayed in research. Clearly we cannot 
eliminate this bias; however, examining the academic age distribution of the sample, shown 
in Figure 7.1, the number of years that PIs in our sample had spent in research was 
distributed across a wide range. Further reassurance about the diversity of our sample is 
provided by the variety of stages our PIs had reached in their careers at the time the case 
study grants commenced: these ranged from pre-PhD through post-doc to lab head and 
head of department. Project Retrosight: Methodology Report  RAND Europe 
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Figure 7-1: Total number of years the PIs responding to our survey had spent in research by 2007 
 
The second point at which we risked biasing our sample was through those PIs who were 
excluded from or declined to take part in the study. The distribution of these exclusions 
across the selection matrix is shown in Figure 7.2. Six PIs declined to participate in the 
study; in one other case initial scoping following the PI’s agreement to take part revealed 
that the grant did not meet our inclusion criteria. In one instance the case study research 
was initiated, and although three interviews were completed, insufficient evidence was 
available to allow full compilation of a full case study report. This case was thus excluded 
from the sample. Finally, in one case the PI had moved to Japan and hence a face-to-face 
interview was not feasible. 
Figure 7-2: Distribution of exclusions: completed case studies are shown as filled circles, refusals 
and exclusions as open circles  
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7.2  Rating behaviour 
Because the ratings produced by the rating panel were a key source of data, it was 
important to examine how much agreement there was among panel members and whether 
they showed similar rating behaviour – i.e. whether some were consistently more generous 
than others. 
First we examined the raters’ behaviour, using the 1827 ratings from the first round of 
rating. It is clear from examining the distribution of the ratings that all the panel members 
behaved similarly in terms of the distribution of their scores. This is shown in Figure 7.3. Project Retrosight: Methodology Report  RAND Europe 
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Figure 7-3: Ratings distributions (by person and category) 
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 The degree of similarity can also be assessed mathematically by comparing the mean and 
median ratings that each panel member gave. Only one panel member did not produce a 
median score of 4, while mean ratings were distributed between 3.3 and 4.3 (see Table 
7.1). We repeated the same analysis again after the ratings workshop and found that the 
behaviour of panel members had become even more similar. 
 
Table 7-1: Summary of the mean and median ratings pre- and post- workshop 
 
Pre-workshop Post-workshop 
Mean  Median Mean Median 
Rater 1  3.6  4 3.7 4 
Rater 2  3.8  4 3.7 4 
Rater 3  3.7  4 3.8 4 
Rater 4  4.0  4 4.0 4 
Rater 5  3.3  3 3.6 4 
Rater 6  4.2  4 4.1 4 
Rater 7  4.3  4 4.2 4 
Rater 8  4.0  4 3.9 4 
Rater 9  4.3  4 4.0 4 
 
After assessing the behaviour of our panel to ensure that members were rating in a similar 
fashion, we examined the level of agreement for the ratings they produced for each case 
study in each payback category. To assess this we examined the distributions of ratings and 
calculated the ADM for each case study in each payback category. Figure 7.4 shows a 
sample of post-workshop distributions of ratings for the knowledge production, informing 
policy and product development and broader economic benefit categories. We show these 
three categories as they demonstrate the range of agreement levels produced. 
 Project Retrosight: Methodology Report  RAND Europe 
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Figure 7-4: Ratings agreement 
 
 
 
ADM represents the average deviation of ratings in a payback category from the median 
rating in that category: the greater the deviation, the greater the diversity of ratings. Using 
the ADM measure we could show that agreement in all of the categories improved between 
the pre-workshop and post-workshop scores, as shown in Figure 7.5, where Wave 1 gives 
the ratings prior to the workshop and Wave 2 shows the adjusted ratings after the 
workshop discussions. As discussed previously, we were not attempting to reach consensus 
among raters, merely to reduce differences in understanding. Although the level of 
agreement improved, the workshop process changed relatively few of the median ratings 
for the individual categories within the case studies – 42 of the 203 (21%) changed, with 
the majority of these changes being a shift of 1 (37 changes, 18% of total ratings). These 
tests reassured us that our rating process was robust and that there was a similar 
understanding among raters of level of payback for each case study in each category. 
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Figure 7-5: Average deviation from the median before and after the workshop 
 
7.3  Confounder analysis 
We identified three key variables that might confound our findings: the basic biomedical 
versus clinical distinction between case studies, the scope of the studies, and studies that 
produced negative results.  
For each of these potential confounders we carried out a sensitivity analysis to test whether 
they were likely to affect our findings. 
7.3.1  Clinical and basic biomedical distinction 
Although the concept of distinct categories of basic biomedical and clinical research is 
almost universally accepted in medical research, it can be very hard to decide exactly how 
the two different types of research should be defined. There is always likely to be some 
research that does not sit obviously in either category or which deliberately incorporates 
elements of both.  
As discussed in Chapter 3, during the case study selection process we found that each of 
our funders had a slightly different idea of the distinction between basic biomedical and 
clinical research. The definitions we used in the selection of case studies for Project 
Retrosight were, therefore, a hybrid of our funders’ definitions:  
•  basic biomedical – focuses on normal or abnormal function at the molecular, 
cellular, organ or whole body level; 
•  clinical – focuses on patients, better diagnostics or treatments and increasing 
quality of life. 
These were the definitions we asked PIs to use in classifying their own research for our 
survey; but because the basic biomedical/clinical distinction is not universally used, we 
wanted to test whether our observations would be robust against alternative definitions. Project Retrosight: Methodology Report  RAND Europe 
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We therefore tested the internationally recognised Frascati Manual classification published 
by the OECD
5 and a more informal definition of whether or not the research involved 
direct contact with patients. By applying these two alternative definitions to each case 
study we were able to gauge the clarity and reliability of the classification system that we 
initially used in selecting grants. Each definition was applied independently by one 
member of the research team. The results of the comparison (Figure 7.6) show a generally 
good agreement between the PIs’ definitions and the Frascati Manual, and even closer 
agreement with the “touches patients” definition. 
To examine whether changes to the classification of the case studies affected our 
observations of factors associated with impact, we tested the effect of “flipping” the case 
studies where our three sets of definitions had least agreement. The results of this 
robustness testing are discussed in relation to each factor in the Policy Report in which we 
discuss our findings (Wooding et al., 2011). 
 
Figure 7-6: A comparison of the alternative research type definitions as applied to the case studies 
 
 
7.3.2  Case study scope 
Nearly all scientific research is undertaken in the context of a body of work being 
conducted by the researcher over a period of time and in collaboration with a number of 
colleagues. Such issues of attribution are discussed in the Policy Report (Wooding et al., 
2011). One particular aspect of attribution relevant to this project was case study scope; we 
wanted to test whether the fact that different case studies had different degrees of overlap 
with other research being carried out by the group affected our assessments of level of 
impact. 
                                                       
5 In order to test agreement with our basic biomedical/clinical definition we treated Frascati basic research as 
equivalent to basic biomedical and Frascati applied research as equivalent to clinical. RAND Europe  Data characterisation and robustness testing 
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While some studies of the impact of research attempt to examine the whole portfolio of 
research over a given time period, we wanted to focus on specific research grants in order 
to measure the payback from research funding. Hence one potential confounding factor 
for Project Retrosight was the actual scope of the research in our sample case studies. 
Our main concern was that in at least some cases the impacts we identified would, in 
reality, be the result of a longer or broader body of work and of multiple sources of 
funding. We therefore had to find a way of isolating the impacts generated by the specific 
grant we were studying from the impact generated by the PIs’ previous work, their later 
research and any body of work or research funding that happened concurrently.  
This was done by analysing the case study summaries, reviewing the appropriate passages 
of case study text and carrying out two brief analyses of scope based on the focus of the 
research. We then combined our observations and used them to grade the scope of each 
case study. 
We assessed the level to which each case study included impacts derived from the PIs’ 
previous work, wider concurrent research/funding and subsequent work, and graded each 
on a scale of three: low (assigned a value of 0); moderate (assigned a value of 1); and high 
(assigned a value of 2).  
Generally speaking, neither the existence of previous or contemporaneous research, nor 
evidence that the PI was receiving concurrent funding, led automatically to a high score for 
scope. Rather, the scores indicating a high level of scope were given when the impacts 
described could to some extent be associated with previous or wider research. Particular 
problems arose in relation to rating the scale for contemporaneous research because it was 
sometimes very difficult to tell if a wide range of related contemporaneous studies being 
conducted by the PI’s team or lab was contributing to the impacts described in the case 
study. Sometimes comments in the detailed case studies give clues: for example, one PI 
stated that the grant from the NHF of Australia covered just a quarter of his project; 
another stated that there was no overlap in terms of funding between his existing projects 
and the project that formed the subject of the case study. 
It was decided to take the combined score from the two scales for previous research and 
contemporaneous research/funding and use this to decide whether scope was a confounder. 
The third scale (impact attributed to follow-on research) was discounted because it seemed 
logical that the impacts from follow-on research can and should to some extent be credited 
to the original project. We saw no relationship between the extent of overlap with previous 
or contemporaneous work and academic or wider impact. This reassured us that scope was 
not a confounding factor. 
7.3.3  Negative or null findings 
We classified five of our case studies as reporting negative or null findings. The concept of 
negative or null results has various definitions
6; we use it to refer to studies that fail to 
confirm or disprove a hypothesis, or those that disprove a hypothesis and hence preclude 
further work (for example, by demonstrating the absence of a link between two systems). 
                                                       
6 See the editorial guidelines of Journal of Negative Results in Biomedicine and Journal of Negative Results (Ecology 
and Evolutionary Biology). Project Retrosight: Methodology Report  RAND Europe 
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As we expected negative or null findings to be independent of other factors that might 
influence impact, we were concerned that a coincidental association between this and a 
second factor could lead us to make inaccurate observations. We therefore tested the 
distribution of case studies with each factor associated with impact both before and after 
excluding case studies with negative or null findings – the results of this analysis are 
discussed in the Policy Report (Wooding et al., 2011). 
We were concerned about negative findings because the available literature suggests that 
they are less likely to be published than positive findings; this suggests that they will be 
associated with lower impact (Gould, 1993). We also think it is likely that our 
methodology may underestimate the impact of studies with negative findings, as it is likely 
to be harder to evaluate the absence of an impact – an area of research that is not pursued, 
saving money for more productive research – than an impact that did materialise.   
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CHAPTER 8  Analysis 
The final stage of the project was to carry out a cross-case analysis of the case studies to 
learn more about the process of cardiovascular and stroke research and to identify factors 
that appeared to be associated with the successful translation of research outputs into 
impacts on policy, improvements in health care and wider economic benefits. 
8.1  Deriving impact categories 
Once we had quantified the payback from each case study, in each payback category, we 
examined the median ratings to look for patterns. We were concerned that identifying 
factors associated with high impact in all five payback categories would be unmanageable 
and so, if possible, we wanted to reduce the number of payback measures. We found that 
grouping the first two payback categories and the last three allowed us to produce two 
mutually exclusive groupings that also grouped the payback categories with the highest 
correlation (Figure 8.1). 
  
Table 8-1: The correlations between ratings in each payback category 
   Knowledge  Research Informing Health &  Broader 
   production  targeting & policy & health economic 
   capacity product sector benefits 
   building development benefits   
KP  1 0.424 0.112 0.106 0.036 
      
RT  0.424  1 0.286 0.334 0.187 
    
IPPD  0.112  0.286 1 0.748 0.441 
    
HHSB  0.106  0.334 0.748 1 0.52 
    
BEB  0.036  0.187 0.441 0.52 1 
      
Coefficients in bold are significant at a 0.01 level
Spearman's rho and 2-tailed significance; n = 261 (29 projects x 9 raters) 
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We grouped the payback categories in this fashion to produce two impact categories: 
academic impact, encompassing knowledge production and research targeting and capacity 
building; and wider impact, encompassing informing policy and product development, 
health and health sector benefits, and broader economic benefits (Figure 8.1). These 
groupings are also intuitively attractive, in that our first category covers impacts affecting 
science and/or the research system, while our second represents impacts on broader society. 
 
Figure 8-1: Payback categories and impact groupings 
 
 
In order to examine similarities and differences between high- and low-impact research, we 
first needed to divide our case studies into these groups. For each of the academic and 
wider impact categories we sorted the complete list of case studies by impact and 
alternately took one case study from the top (high-impact group) and one from the bottom 
(low-impact group) until the middle part of the scale between the two groups contained 
ten case studies. Case studies with tied scores were included or excluded to ensure that the 
gap was at least ten. This resulted in the complete list being divided as closely as possible 
into three equal groups (see Figure 8.2 for diagrammatic representation of the process). As 
there was some uncertainty in our measures of impact we used a middle impact group to 
ensure that we had a clear distinction between our high and low impact cases, rather than 
two overlapping groups. RAND Europe  Analysis 
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Figure 8-2: A diagrammatic overview of the analysis process to identify factors associated with 
impact 
 
This sorting process gave us six groups of case studies: high, mid and low academic impact; 
alongside high, mid and low wider impact. There was overlap between the case studies 
which appeared in the high academic impact group and those which appeared in the high 
wider impact group, but there were also differences, as we would expect from the low level 
of correlation between early and late payback categories. There were similar differences 
between the mid- and low-impact groups. These overlaps are shown in Table 8.2. We also 
did a similar grouping of impact after splitting case studies into basic biomedical and 
clinical categories, as shown in the lower half of Figure 8.2. Again, although the groupings 
are similar, some case studies end up in different groups; for example, some basic Project Retrosight: Methodology Report  RAND Europe 
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biomedical case studies classified as mid wider impact move to the high wider impact 
category when only basic biomedical case studies are considered (see Table 8.3). 
 
Table 8-2: Overlap between high, mid and low groupings for academic and wider impact 
  High academic Mid academic Low academic 
High wider  4 4 1 
Mid wider  3 2 5 
Low wider  2 4 4 
 
Table 8-3: Overlap between the high, mid and low groups for all cases studies versus the 
groupings for basic and clinical case studies separately  
Academic 
impact 
High basic 
biomedical
Mid basic 
biomedical 
Low basic 
biomedical
High 
clinical 
Mid 
clinical 
Low 
clinical 
High all  5   4  
Mid all   4  2 2 2  
Low all     42 4  
 
Wider 
impact 
High basic 
biomedical
Mid basic 
biomedical 
Low basic 
biomedical
High 
clinical 
Mid 
clinical 
Low 
clinical 
High all  5   5 1  
Mid all   4  4 2 
Low all     62  
 
8.2  Identifying factors associated with research impact 
In this stage of the analysis we aimed to identify factors common in high-impact research 
but not shared by (or at least uncommon in) low-impact research. As explained above, we 
considered academic impact and wider impact separately because the two were not well 
correlated – a case study could have high academic impact but low wider impact, or vice 
versa. 
Four members of the research team (MB, JG, AP and SW) each took one of four impact 
groups (academic/high impact, academic/low impact, wider/high impact, wider/low 
impact) and independently examined four of the relevant case studies in their category to 
look for common factors. The two researchers looking at high-impact case studies then 
compared their findings and identified emerging factors associated with impact that they 
had both observed. The two researchers examining low-impact case studies followed the 
same procedure. RAND Europe  Analysis 
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This exercise was followed by a discussion of the factors identified, involving the whole 
research team; during this discussion the team assembled a core set of factors on which to 
focus. These were classified as factors of high importance and factors of potential interest 
that lacked further evidence and were not strong enough to be the main focus. Figure 8.3 
shows the complete list of factors compiled at this stage. 
Figure 8-3. Factors coded for in the 29 case studies. Bold italics indicate factors analysed and 
discussed in the Policy Report (Wooding et al., 2011) 
•  Clinical motivation 
•  Basic biomedical research in a clinical setting 
•  Strategic thinking 
•  Collaboration with other researchers 
-  Collaboration on resources 
-  Collaboration on design 
-  International collaboration facilitating research 
-  International collaboration facilitating impact 
-  Other 
•  Engagement with practitioners and patients 
•  Collaboration with industry 
•  Negative or null findings 
•  Initial rejection of application 
•  Basic biomedical and clinical research perspectives are combined 
-  In the PI 
-  In the team 
•  Research only has basic biomedical perspective 
•  Research only has clinical perspective 
•  Career stage of PI 
•  Field transition 
•  New method in the field 
•  Confronting prejudice or entrenched viewpoints 
•  Policy collaboration / engagement with policymakers 
•  Fashionable area of science 
•  Initial cutting of grant resulted in follow-on/extension of funding 
•  Lack of standard commercialisable outcomes 
•  PI has long term record in field 
•  Follow on research produced negative findings 
•  Senior champion for the PI’s work 
•  Use of animals in research Project Retrosight: Methodology Report  RAND Europe 
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Each person then reread their initial four case studies, coding for the agreed factors, took 
the opposite end of the other impact category (for example, switched from academic/low 
impact to wider/high impact) and coded the remaining cases in that category.  
The coding at this stage was done in NVivo, a widely used software package for qualitative 
analysis
7. It allows text relevant to each factor to be highlighted and coded to the factor, 
and for the coding of all four researchers to be combined in one file. 
Each factor was analysed quantitatively and qualitatively. Quantitative analysis was carried 
out in NVivo to determine the number of case studies in which each factor occurred. The 
frequency at which these factors occurred was compared in the high- and low-impact 
groups defined previously, both for academic and for wider impact categories. 
In addition to this overall comparison, each of these ranking lists was split out into basic 
biomedical and clinical research (so there were four separate ranking lists: basic 
biomedical/academic, clinical/academic, basic biomedical/wider and clinical/wider). Again, 
high- and low-impact groups were determined from these scales. The same method of 
defining high- and low-impact groups was used again, with the gap between high and low 
groups set at four case studies rather than ten due to the smaller number of cases in each 
list. 
The following list of analyses was conducted in NVivo (in each instance, the frequency of 
occurrence of each factor was compared). 
•  High- vs low-impact academic across all case studies 
•  High- vs low-impact academic basic biomedical case studies 
•  High- vs low-impact academic clinical case studies 
•  High- vs low-impact wider across all case studies 
•  High- vs low-impact wider basic biomedical case studies 
•  High- vs low-impact wider clinical case studies 
•  High- vs low-impact in both academic and wider across all case studies 
•  High- vs low-impact in both academic and wider basic biomedical case studies 
•  High- vs low-impact in both academic and wider clinical case studies 
The last three were not used in subsequent interpretation because of the small numbers of 
case studies with high/low scores in both impact categories. The project team met to 
discuss the analysis and identify emerging findings. 
Qualitative analysis was done by assigning each factor to a coder who reviewed all the 
mentions of that theme to ensure consistency of interpretation. Resource limitations meant 
                                                       
7 We used NVivo 8, which has now been updated; QSR International. NVivo software. 
http://www.qsrinternational.com/products_nvivo.aspx [Accessed 16 December 2010] RAND Europe  Analysis 
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that we could not double-code cases, but by coding first by case study and then by factor 
we hope to have removed the majority of inconsistencies. 
Key messages were drafted and supporting evidence identified for discussion at the 
Emerging Findings workshop. 
8.3  Emerging Findings workshop 
To test and review our emerging conclusions and help us develop policy-relevant findings 
we convened an international workshop in May 2010 with a range of stakeholders from 
the biomedical and cardiovascular research community (as shown in Table 8.4). 
 
Table 8-4: Emerging Findings workshop participants 
Name  Affiliation
Liz Allen  Wellcome Trust
Stefano Bertuzzi Office of Science Policy, National Institutes of Health, USA 
David Cox  Research and Development, Department of Health 
Vicki Crossley Economic and Social Research Council
Lisa Croucher Arthritis Research UK
Sally Davies Research and Development, Department of Health 
Chris Henshall University of York
Liam O’Toole Arthritis Research UK
Jeremy Pearson British Heart Foundation
Rachel Quinn The Academy of Medical Sciences
 
At the workshop we presented the methods, results and emerging findings of the study. 
The bulk of the workshop was then given over to discussion of the issues raised by each 
stage of the project. This workshop was extremely valuable in helping refine our thinking 
and suggesting additional focuses for further iterations of the quantitative and qualitative 
analysis outlined above. Following the workshop we revisited in detail the evidence behind 
each of our findings and further investigated the subtleties of the data. We refined our 
observations based on this analysis and developed the policy implications outlined in our 
main policy report (Wooding et al., 2011).   
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Appendix A: PI Survey 
Project Retrosight Survey  
As a research grant holder in cardiovascular disease in the early 1990s, we would like to ask 
you to kindly participate in a short survey (around 5 minutes to fill in) for a multi-national 
research project looking at the impacts of CVD research over long time periods. The 
research is being supported by a consortium consisting of the following bodies:  
English Department of Health  
British Heart Foundation  
UK Stroke Association  
Canadian Institute of Health Research  
Heart and Stroke Foundation of Canada  
New Zealand National Heart Foundation  
Health Research Council of New Zealand  
National Heart Foundation Australia. 
The survey is a preliminary phase of the research, prior to in-depth case study research of 
specific grants funded by the supporters shown above. 
In order to proceed to the survey, please enter the password you were provided in the 
recruitment email below: 
 
(the password should be of the form of three characters followed by three numbers) 
[second page] 
Project Retrosight Survey  
Our database indicates that you were involved with the following study: 
No.   Grantholder   Year   Title   Funder  
[grant details] 
Can you confirm that this is correct? 
Yes, this is correct Project Retrosight: Methodology Report  RAND Europe 
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[if ‘No’ to correct grants question, then taken to page] 
Our database indicates that you were involved with the following study: 
Delete?  No.   Grantholder   Year   Title   Funder  
{details editable here} 
From here, are taken to section one of the survey. 
[If yes – new page] 
We would like first to ask about you as a researcher, and in section two we would like to 
ask you specifically about your research project(s). 
Section one: 
1.  As we are trying to provide a representative sample of researchers, based on the 
population during the early 1990s, we would like to be able to reflect the gender 
proportions seen at that time. Since gender is not routinely recorded by research 
funders, please could you indicate your gender below?  
Male [ ]   Female [ ]  
2.  As of 2007, how many years have you been actively involved in research? (i.e. 
subtract career breaks, maternity leave, etc). 
a.  Post PhD (if applicable) [  drop down menu of 1-50+  ] 
b.  In total [   drop down menu of 1-50+    ]  
 
Section two: 
We would now like to ask you specifically about the following project: 
Grant name. (year) 
Please answer the following questions with reference to this project. 
3. Was the research funded clinical or basic biomedical according to the following 
definitions?  
   Clinical – focuses on patients, on better diagnostics or treatments, and on increasing 
quality of life.  
   Basic biomedical – focuses on normal or abnormal function at the molecular, cellular, 
organ or whole body level.  
4. Did the research team involve scientists or approaches drawn from more than one 
scientific discipline?  
   It only involved one discipline within health  
   It encompassed more than one discipline within health  
   It encompassed more than one discipline from outside health research  
No, this is not correct 
Next RAND Europe  Appendix A: PI Survey 
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5. Was one of the research team a practicing clinician at the time of the research?  
   Yes  
   No 
6. How many publications (i.e. peer-reviewed articles, editorials, books, chapters and 
publicly available reports) arose primarily from your project? (please do not include 
abstracts)  
    --- Please select ---[ drop down menu 0, 1–4, 5–9, 10–19, 20+ ] 
7. Have the project findings, methodology or theoretical developments contributed to 
further research by researchers outside the immediate research team (other than systematic 
reviews or meta-analyses, conducted by others)?  
   Yes  
   No  
8. Has participation in this research led to higher degrees (e.g. PhD, MD) for any 
members of the project team and if so, how many?  
   None  
   One  
   More than one  
9. Research findings can be used in policy making (either to change policy or continue 
with the existing policy) in various ways, across different levels of the system, and with 
varying degrees of impact. These levels of the health system range from decisions taken at a 
major level, e.g. national public policy, reimbursement decisions by the Ministry of 
Health, clinical guidelines from nationally respected bodies; to more minor level, e.g. the 
policies of a local health care unit or a local group of professionals. What level of decision 
making did your project impact?  
   Major  
   Minor  
   None  
10. Research findings might have made a major or minor degree of impact on particular 
decision(s). A major impact would include being cited as one of the main pieces of 
evidence behind the decision. A minor impact would include: evidence of the finding 
being considered as the policy was developed, some reference to it in a guideline. What was 
the degree of importance of the project in the decision making?  
   Major  
   Minor  
   None  
11. Did the research project lead to any involvement with or a product development by 
industry?  Project Retrosight: Methodology Report  RAND Europe 
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   No involvement  
   Research collaboration  
   Licenced patent  
   Spin out company  
   Product developed by industry  
12. Research findings can influence behaviour of health practitioners (or the public) in 
various ways (both at different levels of the system and with different degrees of impacts). 
Levels can range from major (i.e. at a wide national or even international level) to minor 
(i.e. at a local unit level). At what level of the health system were your research findings 
applied?  
   Major  
   Minor  
   None  
13. Research findings might have made a major or minor degree of impact on the 
particular practice(s) used in healthcare. A major impact might be identifying a new 
surgical procedure that is taken on; a minor impact might be modifying a current well-
established practice. What was the degree of importance of the project on healthcare 
practice?  
   Major  
   Minor  
   None 
 
 
[endpage] 
Your response has been saved. 
Thank you for helping with this research. 
If you have any questions on this survey please contact Eddy Nason at RAND Europe by 
email: nason@rand.org 
 
Next  
67 
Appendix B: PI interview protocol 
Introduction: 
 
RAND Europe is investigating the pathways upon which CVD research is built. RAND 
Europe is a non-profit policy research organization, with an interest in research policy. In 
order to carry out this project we are building a series of case studies around research grants 
that were awarded in the early 1990s. 
 
RAND Europe works in a number of policy areas. This work is being carried out within 
our Science and Technology program which has an emphasis on research policy. Our 
previous work in this area includes: Payback studies of research impact on Arthritis 
Research Council grants and ESRC grants; a study for the National Audit Office on how 
Government Departments commission research published as ‘Getting the Evidence’; and a 
study to investigate the views of academics with respect to research assessment for the 
Robert’s Review of Research Assessment. 
 
We are looking at both how the findings produced by the grant were developed and 
translated; and also, how the support developed the careers of researchers.  
 
You will probably want to quickly talk them through the Payback model at this stage. 
 
You should also emphasize that not all the questions will be relevant to their research project, 
and indeed we wouldn’t expect them all to be. 
 
You shouldn’t stick to the protocol as written, it just provides guidance of the areas you should 
aim to cover. During your desk research you will have identified additional questions that you 
will want to ask and it’s probably best to add these to the protocol. 
 
STAGE 0: Opportunity Identification/Research needs Assessment 
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1.  What was the original impetus for your project?   Solely scientific curiosity?  The 
need to fill certain gaps in knowledge?  Targeting of a particular disease state? Your 
own clinical experience? 
 
2.  How far was your identification of the research topic influenced by: 
 
a.  Research you had done before? Funded by whom? 
b.  The research of others? If so how did you hear about this research? 
 
3.  How much interaction was involved in determining your choice of research topic?  
With funders? With peers internationally in a specific research community? With 
representatives of patient or practitioner groups? Did institutional conditions such 
as lab space, equipment, availability of researchers affect the research proposal? 
 
 
INTERFACE A: Peer review/ Project Specification, Selection and 
Commissioning 
 
1.  Were any changes requested during the peer review/ project selection process? 
 
2.  Was there any negotiation involving potential users (users in any sense – maybe 
clinicians, maybe patients, maybe other scientists) during the project specification 
or commissioning processes? 
 
3.  Was there any involvement of practitioners, or even policy-makers, in the process 
of project selection? 
 
4.  Had your research not been funded by the organisation that did fund it, do you 
think any other body would have funded the research? 
 
STAGE 1: Inputs to Research 
1.  Check on cost of project. Were any other resources used on the project, for 
example where did the overhead costs come from? Was there soft or core funding? 
 
2.  What was the institutional setting (hospital, university, research institute) for the 
research? 
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3.  Who were the main researchers? What was their level of research experience and 
seniority at that time and in particular had they previously worked in the research 
area?  
4.  What inputs of the following where important (provide a copy of the diagram and 
discuss around the topics): 
 
STAGE 2: Processes 
5.  Did the methods proposed prove to be appropriate? Were all of the avenues of 
research suggested in the proposal successful? 
 
6.  Was there any interaction with potential users of the research during the research 
processes? 
 
7.  What was your role as PI in the team and the research process? Facilitator? 
Research director? 
 
8.  What was the role of collaborators in the research process (both academic and 
industrial)? 
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STAGE 3: Primary Outputs 
This section is reliant on the identification of a grant or piece of research from the 1989-
1993 period. 
1.  Identify any publications based on the grant that has been selected and from the 
subsequent stream of work following the grant. 
 
2.  Which publications do you think were most important from this project and why? 
(Then reveal citation scores and compare results – based on preliminary Web of Science 
citation records or bibliometrics if available) 
 
3.  Did this work have any impact on the agenda for your subsequent research? 
 
4.  Did it make any impact on the career of any of the research team eg contribute to 
research training in terms of research degrees or the gaining of additional skills? 
Enable them to establish themselves in the field? Assist in gaining further? Helping 
the lead researcher to build a team of researchers?  
 
5.  Are you aware of any other researchers who have built on this work or used the 
methods you developed? What is the role of collaborators in this? 
 
6.  Over what type of time-scale do you think your research influenced subsequent 
research. 
 
7.  Did the research spawn a new area of investigation or make a major impact on the 
approach used in subsequent research? If so would you go so far as to say it led to a 
paradigm shift in the understanding of a sub-field of arthritis or rheumatology? 
 
8.  If the research was clinical or related to AHP were any basic researchers also 
involved? If so did this influence their attitude to clinical or AHP research? 
 
9.  Were any health practitioners involved in assisting with the research, and if so did 
it have any impact on their attitude towards implementing research findings in 
general? 
 
10. Did the project play any part in making the existing stock of international 
knowledge more applicable/acceptable in the UK? Did the project allow work 
from another field to be applied to arthritis and rheumatology or vice versa? 
 
11. Has the research been included in any formal reviews? In clinical science this would 
be a question about systematic reviews, in basic science it is a more general question. 
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12. Have you had any impact outside the field of research you are working in? 
 
 
INTERFACE B: Dissemination 
1.  Apart from publications, what attempt did you make to disseminate the findings 
to academic audiences? More widely? Did you work with funders or stakeholders 
to do this? 
 
2.  Did you use specially designed dissemination approaches to particular audiences, 
for example policy briefs for policymakers? What were the most effective 
mechanisms for this? 
 
3.  What was the role of your networks in dissemination? 
 
4.  Did you receive support from funders/employers for dissemination? What form 
did this take? 
 
STAGE 4: Secondary Outputs 
1.  Has the research been cited directly in any clinical guideline, audit criteria or 
similar document from a professional body or public policymaking body at 
national or local level?  
 
2.  Do you know how far the research directly influenced the formulation of any 
policy, or the realisation that a policy was needed?  
 
3.  Has any of the subsequent research by yourself or others that built on the project 
been cited in any clinical guideline, audit criteria or similar document from a 
professional body or public policymaking body at national or local level? Do you 
think this might happen in future? 
 
4.  Did the research from your project lead to any patent/licences, was it taken up by 
industry/has it contributed to any commercial products? 
 
5.  If the research has made some impact, what are the key reasons for this? If it has 
failed to have an impact what are the reasons for this? What barriers were there to 
the research having an impact/being translated? What factors facilitated the 
research having an impact/being translated? 
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6.  Has your research had an impact on teaching for clinicians? 
 
7.  Has any advisory role to government, hospitals, industry led to an impact from 
your research? How did this come about? 
 
Mapping exercise 
8.  Use a large sheet of paper (flip chart sheet) to map with the PI, the research. Both 
forwards from the grant under discussion and backwards to understand key inputs 
to the grant (people, money, expertise – see inputs section). Error! Reference 
source not found. shows an example of what this might look like. 
 
STAGE 5: Applications 
1.  Have the findings from the research influenced practitioners directly through 
them reading the articles or hearing a presentation about the research?  Has it 
made any impact on practice through clinical guidelines or policies based either 
specifically on the research or on other research that built on your research? Has 
any impact been local, regional, national or international? 
 
2.  If the research has been taken up by industry, do you know what level of sales has 
been achieved by any product to which it contributed? 
 
3.  Do you expect any greater take-up of the findings in the future? Where? 
 
4.  Has there been an impact on practice through your own clinical work (if you have 
any)? What has been the knock on effect of that on other clinicians?  
 
STAGE 6: Public Engagement 
1.  Depending on answers to previous questions about involvement of the public in 
shaping the research agenda, ask how far there has been any interaction with 
patients, patient groups or the wider public about the findings and their 
implication. Has this led to any improvement in the way patients manage their 
own care or interact with therapy? Or had any impact on public attitudes to 
medical research? 
 
2.  Did engagement with the public/patient groups lead to changes in the researchers’ 
perceptions of these groups? 
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3.  Has there been a change in attitudes in the research community to involvement of 
the public since the time when this research was conducted? 
 
STAGE 7: Final Outcomes 
1.  If the research has made impact on policy or practice, or on the behaviour of the 
public, is there any way of assessing the benefits in terms of: patient health gain? 
Qualitative improvements in the way the service is delivered that increase patient 
and/or practitioner satisfaction? Cost savings? 
 
2.  If it is possible to assess the potential benefit for one patient, approximately how 
many patients might be able to benefit from the improved therapy or organisation 
of the service? 
 
3.  If the improved therapy based on the research has resulted in a health gain, will 
this also result in fewer days lost from work/ decreased benefits payments/ 
decreased visits to secondary healthcare? 
 
4.  If the research has resulted in commercial development is anything known about 
the amount of employment generated, the level of import substitution, or the 
revenue generated for the company by the product? 
 
Other general questions 
1.  Who else should we speak to about your research? 
 
2.  Are there other questions we should have asked or things that you want to talk 
about? 
 
3.  Are you happy for us to contact you to follow up on details arising from the case 
study research? 
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Appendix C: Non-PI interview protocol 
Introduction: 
 
RAND Europe is investigating the pathways upon which CVD research is built. RAND 
Europe is a non-profit policy research organization, with an interest in research policy. In 
order to carry out this project for ARC we are building a series of case studies around 
research grants that were awarded in the early 1990s. 
 
RAND Europe works in a number of policy areas. This work is being carried out within 
our Science and Technology program which has an emphasis on research policy. Our 
previous work in this area includes: Payback studies of research impact on Arthritis 
Research Council grants and ESRC grants; a study for the National Audit Office on how 
Government Departments commission research published as ‘Getting the Evidence’; and a 
study to investigate the views of academics with respect to research assessment for the 
Robert’s Review of Research Assessment. 
 
We are looking at both how the findings produced by the grant were developed and 
translated; and also, how the support developed the careers of researchers.  
 
You will probably want to quickly talk them through the Payback model at this stage. 
 
You should also emphasize that not all the questions will be relevant to their research 
project, and indeed we wouldn’t expect them all to be. 
 
You shouldn’t stick to the protocol as written, it just provides guidance of the areas you 
should aim to cover. During your interview with the PI/Lead researcher you will have 
identified additional questions that you will want to ask and it’s probably best to add these 
to the protocol prior to the interview. Project Retrosight: Methodology Report  RAND Europe 
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General questions 
 
1.  What is your current position? What was your position during the lifetime of the 
grant? 
 
2.  How did you find out about the researcher? The research project in particular? 
 
STAGE 0: Opportunity Identification/Research needs Assessment 
 
1.  Did the project fill certain gaps in knowledge? Was there an urgent need for it 
(either scientifically or clinically)? 
 
2.  Did you have any input into the identification of the research topic/ funding 
body/ research team identification? 
 
3.  Do you know of other research at the time that suggested this project should be 
performed (either your own research or others)? What was going on in research in 
this area at the time? Was this a novel project? 
  
4.  [For co-researchers] How much interaction was involved in determining your 
choice of research topic?  With funders? With peers internationally in a specific 
research community? With representatives of patient or practitioner groups? Did 
institutional conditions such as lab space, equipment, availability of researchers 
affect the research proposal? 
INTERFACE A: Peer review/ Project Specification, Selection and 
Commissioning 
 
1.  Were you involved in any negotiation during the project specification or 
commissioning processes? 
 
2.  Had the research not been funded by the organisation that did fund it, do you 
think any other body would have funded the research? 
 
STAGE 1: Inputs to Research 
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1.  What inputs of the following where important in helping the project be a success? 
(See diagram) 
STAGE 2: Processes 
 
1.  From what you know, from what you know, were the methods used for the project suitable for the study? Were 
they groundbreaking/ building on previous research? 
 
2.  Was there any interaction with potential users of the research during the research 
processes? 
 
3.  If you were a collaborator in the research process, what was your role? (both 
academic and industrial)? 
 
STAGE 3: Primary Outputs 
 
1.  What specific outputs of the research/researcher do you know? What is your view 
on their work in general? On this project/subject area? 
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2.  Which publications do you think were most important from this project and why? 
 
3.  Did this work have any impact on your own research/ the research field as you 
know it? 
 
4.  [For co-researchers] Did it make any impact on the career of any of the research 
team eg contribute to research training in terms of research degrees or the gaining 
of additional skills? Enable them to establish themselves in the field? Assist in 
gaining further? Helping the lead researcher to build a team of researchers?  
 
5.  Are you aware of any other researchers who have built on this work or used the 
methods? 
 
6.  Over what type of time-scale do you think this research influenced subsequent 
research? 
 
7.  Did the research spawn a new area of investigation or make a major impact on the 
approach used in subsequent research? If so would you go so far as to say it led to a 
paradigm shift in the understanding of a sub-field of CVD research? 
 
8.  What was the relationship between the clinical and basic aspects of the research? If 
the research was clinical or related to AHP were any basic researchers also 
involved? If so did this influence their attitude to clinical or AHP research? 
 
9.  Do you know of the research being taken on board and used in practice? What 
facilitated this? 
 
10. Has the research been included in any formal reviews that you know of? In clinical 
science this would be a question about systematic reviews, in basic science it is a more 
general question. 
 
11. Has the research had any impact outside the immediate field of research? Did the 
project play any part in making the existing stock of international knowledge more 
applicable/acceptable in the UK?  
 
INTERFACE B: Dissemination 
 
1.  Apart from publications, what other dissemination methods do you know of from 
this project? (Could be seminars, books, teaching, practice clinics, talks, RAND Europe  Appendix C: Non-PI interview protocol 
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presentations, etc…)? Where was this other dissemination (funders/ stakeholders 
conferences etc.)?  
 
2.  Was any particular method of dissemination useful for you? Useful for specific 
types of information? 
 
3.  What was the role of personal networks in this dissemination in your opinion? 
 
STAGE 4: Secondary Outputs 
 
1.  Has the research been cited directly in any clinical guideline, audit criteria or 
similar document from a professional body or public policymaking body at 
national or local level that you know of?  
 
2.  Do you know how far the research directly influenced the formulation of any 
policy, or the realisation that a policy was needed?  
 
3.  Has any of the subsequent research by the researcher, or others that built on the 
project, been cited in any clinical guideline, audit criteria or similar document 
from a professional body or public policymaking body at national or local level? 
Do you think this might happen in future? 
 
4.  Do you know of any patent/licences or industry take up/contribution to any 
commercial products that arose from the research? 
 
5.  If the research has made some impact, what are the key reasons for this? If it has 
failed to have an impact what are the reasons for this? What barriers were there to 
the research having an impact/being translated? What factors facilitated the 
research having an impact/being translated? 
 
6.  Has the research project had an impact on teaching for clinicians? 
 
7.  What other routes do you know of that could lead to an impact from the research 
(e.g. any advisory role to government, hospitals, industry)? How would/did this 
come about? 
 
STAGE 5: Applications 
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1.  Have the findings from the research influenced practitioners directly through 
them reading the articles or hearing a presentation about the research?  Has it 
made any impact on practice through clinical guidelines or policies based either 
specifically on the research or on other research that built on your research? Has 
any impact been local, regional, national or international? 
 
2.  If the research has been taken up by industry, do you know what level of sales has 
been achieved by any product to which it contributed? 
 
3.  Do you expect any greater take-up of the findings in the future? Where? 
 
4.  Has there been an impact on practice through the clinical work of the researcher 
involved that you know of? What has been the knock on effect of the research on 
other clinicians?  
 
STAGE 6: Public Engagement 
1.  Do you know how far there has been any interaction with patients, patient groups 
or the wider public about the findings and their implications. Has this led to any 
improvement in the way patients manage their own care or interact with therapy? 
Or had any impact on public attitudes to medical research? 
 
2.  Has there been a change in attitudes in the research community to involvement of 
the public since the time when this research was conducted? 
 
STAGE 7: Final Outcomes 
 
1.  If the research has made impact on policy or practice, or on the behaviour of the 
public, is there any way of assessing the benefits in terms of: patient health gain? 
Qualitative improvements in the way the service is delivered that increase patient 
and/or practitioner satisfaction? Cost savings? 
 
2.  If it is possible to assess the potential benefit for one patient, approximately how 
many patients might be able to benefit from the improved therapy or organisation 
of the service? 
 
3.  If the improved therapy based on the research has resulted in a health gain, will 
this also result in fewer days lost from work/ decreased benefits payments/ 
decreased visits to secondary healthcare? 
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4.  If the research has resulted in commercial development is anything known about 
the amount of employment generated, the level of import substitution, or the 
revenue generated for the company by the product? 
 
Other general questions 
 
1.  Do you think that there is anyone else we should speak to about the research? 
 
2.  Are there other questions we should have asked or things that you want to talk 
about? 
 
3.  Are you happy for us to contact you to follow up on details arising from the case 
study research? 
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Appendix D: External peer review materials 
Project Retrosight: Guidelines for expert peer reviewers 
Thank you for agreeing to assist us in this project. Project Retrosight is a collaborative 
project that aims to trace the impact of cardiovascular research funded between 1989 and 
1994. The project aims to examine all forms of research impact, from building research 
knowledge and capacity; to broader health and socio-economic impacts. To do this we are 
using a series of case studies from Australia, Canada and UK. Each case study examines the 
impact of a particular cardiovascular research project funded by the MRC (UK), CIHR or 
HSFC (Canada) or Heart Foundation (Australia). Through this analysis we hope to 
provide a better understanding of the processes involved in achieving impacts and to try to 
identify factors that might facilitate higher levels of impact.  
The project methodology has been used previously to assess the impact of health and 
medical research in a number of areas, including diabetes
8 and arthritis
9. We hope this 
work will help funding bodies involved in the project, and other policy makers, consider 
how they might more effectively support health and medical research. 
To help ensure that the material we are using in this study is as accurate as possible, we 
would like you to review one case-study. This review will not require an assessment or 
critique of the scientific approach or methodology undertaken. Rather we would like you 
to assess whether you think the case-study provides an accurate account of the research 
undertaken and its impact in the scientific and broader community.  
The focus of the case studies is on the impacts: how the research has influenced further 
research and healthcare. The intention is to make these case studies available to an 
                                                       
8 Hanney, Steve, Iain Frame, Jonathan Grant, Philip Green, and Martin Buxton, From bench to 
bedside: tracing the payback forwards from basic or early clinical research - a preliminary exercise 
and proposals for a future study, Uxbridge, Middlesex: Health Economics Research Group, Brunel 
University, 2003. 
9 Wooding, Steven, S R Hanney, M J Buxton, and Jonathan Grant, The returns from arthritis 
research: approach, analysis and recommendations. Volume 1, Cambridge, UK: RAND Europe, 
2004. 
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audience who is unlikely to understand the technical detail of the research, so they have 
been written with only an overview of the work undertaken.  
The case studies are based on relevant documentary evidence, interviews with the lead 
researchers and interviews with other key informants involved in the research undertaken. 
The lead researcher involved in the project has also reviewed the case study and they have 
authorised further use in this study. For each project we are seeking the opinion of two 
experts: one from the same country as the PI and another from different country to add an 
international perspective. 
In your review of this case study, the key questions we would like you to address are: 
•  Does the account appear to correctly characterise the findings, conclusions and 
scientific implications of the research project in question? 
•  Does the account appear to correctly summarise the impacts of the study?  
o  Are impacts claimed that you do not think can reasonably be linked to 
this research? 
o  Are you aware of impacts that might have been missed? 
•  Does the account seem to you to acknowledge research that was being undertaken 
elsewhere around the same time and which might justifiably also claim to 
underpin some of the impacts referred to? 
•  To your knowledge, were there other research teams addressing very similar 
questions in parallel and who effectively published the same conclusions in 
advance of the team in question? 
Additionally we would like you to advise us: 
•  Whether the science involved is adequately described, remembering that the 
accounts are aimed at lay audiences rather than expert scientists? 
We have provided a template for you to outline your responses to these questions as you 
examine the case study. We would appreciate your honest response and any detail you 
could provide about any concerns you might have with the content of the case study. If 
you have reservations about the claims made in the account, please indicate concisely, but 
as precisely as you can, the basis for your concerns. If there is specific literature (papers, 
guidelines, commentaries) that would support your argument or assist us in coming to a 
fair conclusion please cite these if possible. If you have sense that there are important 
inaccuracies in the account but you feel that the particular issue is outside your expertise, 
please suggest the name of someone that might better be able to comment.  
The comments you provide us will be shared anonymously with the lead researcher but 
will otherwise be kept in confidence. 
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Table 1: The standard classification of impacts used in the case studies (with indicative examples) 
 
Payback Category  Example 
Knowledge Production  Number of peer-reviewed journal articles 
High Impact publications 
Research targeting and capacity 
building 
PhDs and promotions 
Additional funding 
Informing policy and product 
development 
Influence on clinical guidelines 
New device developed 
Health and health sector benefits  Improved health attributable to research  
Cost savings to the health sector 
Broader economic benefits  Revenue generated by start up companies  
Employment due to research products (e.g. in start-ups)  
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PROJECT RETROSIGHT: EXPERT PEER REVIEWER 
FORM 
Reviewer: Date: 
Case Study: 
 
The boxes should expand as you type, do not worry if your comments break 
across pages 
 
Does the account in this case study appear to characterise accurately the 
findings, conclusions and scientific implications of the research project in 
question? If you feel there are any inaccuracies in the account, please provide 
further detail and relevant references. 
 
 
 
 
 
 
 
 
 
Does the account appear to correctly summarise the impacts of the research 
project?   
•  Are there impacts claimed that you do not think can reasonably be 
linked back to this project? 
•  Are you aware of likely impacts that may have been omitted? 
 
 
 
 
 
 
 
 
 
 
Does the account included in the case study seem to appropriately 
acknowledge research that was being undertaken elsewhere at  around the RAND Europe  Appendix D: External peer review materials 
87 
same time and which might justifiably also claim to underpin some of the 
impacts discussed in the case study? 
 
 
 
 
 
 
 
 
 
 
 
 
To your knowledge, were there other research teams addressing very similar 
questions in parallel with this research project?  Is there potential that they may 
have published the same conclusions in advance of the team in question? 
 
 
 
 
 
 
 
 
 
 
 
Is the science underpinning the project adequately described? In answering 
this question, please note that the accounts are aimed at lay audiences rather 
than researchers with expertise in the area. 
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Do you have any other comments or suggestions you would like to make about 
the case study you have reviewed? 
 
 
 
 
 
 
 
 
 
 
Thank you for your time. The comments you provide us will be shared 
anonymously with the lead researcher but will otherwise be kept in 
confidence. 
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Appendix E: Rating instructions 
Project Retrosight -- - Guidance for Scorers 
Thank you for agreeing to assist us with the scoring stage of this project. Project 
Retrosight is a collaborative project that aims to trace the impact of cardiovascular 
research. We examined research funded between 1989 and 1994. The project aims 
to examine all forms of research impact, from building research knowledge and 
capacity; to broader health and socio-economic impacts. To do this we use a series 
of case studies from Australia, Canada and the UK. Each case study examines the 
impact of a particular cardiovascular research project funded by the MRC (UK), 
CIHR or HSFC (Canada) or Heart Foundation (Australia). Through this analysis 
we hope to provide a better understanding of the processes involved in achieving 
impacts and to try to identify factors that might facilitate higher levels of impact. 
The project methodology has been used previously to assess the impact of health 
and medical research in a number of areas, including diabetes10 and arthritis11. We 
hope this work will help funding bodies involved in the project, and other policy 
makers, to consider how they might more effectively support health and medical 
research. 
This scoring exercise is a means for us to identify research grants which have had a 
high impact and those which have had a lower impact across a range of categories. 
This will help us in trying to identify common factors across case studies with 
similar levels of impact, and hopefully build a picture of factors which lead to 
research impact.  
To do this, we ask you to score 29 case studies for their level of impact in each of a 
range of payback categories. Each case study relates to one grant awarded between 
                                                       
10 Hanney, Steve, Iain Frame, Jonathan Grant, Philip Green, and Martin Buxton, From bench to 
bedside: tracing the payback forwards from basic or early clinical research - a preliminary exercise 
and proposals for a future study, Uxbridge, Middlesex: Health Economics Research Group, Brunel 
University, 2003. 
11 Wooding, Steven, S R Hanney, M J Buxton, and Jonathan Grant, The returns from arthritis 
research: approach, analysis and recommendations. Volume 1, Cambridge, UK: RAND Europe, 
2004. Project Retrosight: Methodology Report  RAND Europe 
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1989 and 1994 in the field of cardiovascular research. We will also ask you to give 
each case study an overall score and a value for money score. We would like you to 
score the case studies within the set, and not relative to any wider expectations or 
experience. By this, we mean that the level of impact achieved should only be 
scored in comparison to the other case studies presented. Please note that the 
precise scores are not critical, rather they are a means to establish groups of high 
and low impact case studies. In order to help do this effectively, we suggest the 
following approach: 
1.  Familiarise yourself with the case studies by reading over the summaries and 
reviewing the other materials (outlined below) 
2.  When you are ready to start scoring, look through the material relating to a 
particular category of payback for all case studies  
3.  Identify any case studies which have no impact in a particular payback category 
and give them a score of 0 
4.   Select the case study/ies which has/have had the lowest level of impact in that 
category (relative to the other case studies) and give it/them a score of 1 
5.   Select the case study/ies which has/have had the highest level of impact in that 
category (relative to the other case studies) and give it/them a score of 9 
6.   Score the other case studies relative to these benchmarks 
It is possible to have more than one case study scored at 1 or 9 (or any other score). 
Again, note that the aim of this exercise is to distinguish high and low impact case 
studies, so it is not necessary to spend a large amount of time attempting to 
distinguish between case studies with similar levels of impact.  
We would like you to score each case study against the following categories: 
-  Knowledge Production: covers the findings from the project that are 
contained in peer reviewed articles, books etc. 
-  Research Targeting and Capacity Building: includes the ways in which 
further research by the team, or others, builds on the project’s findings and/or 
methods; and the research training gained through the project, especially in 
terms of higher degrees, and contribution to career progression of team 
members.  
-  Informing Policy and Product Development: includes the ways in which 
research informs the development of policies, broadly defined to include 
national legislation, local protocols, clinical guidelines from organisations 
within the health care system and from professional bodies, public health 
advice offered by health service or professional bodies etc; and the use of 
research to inform the development of drugs and devices etc. It can also 
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-  Health and Health Sector Benefits: includes health gains resulting from the 
adoption of the research findings directly by health care professionals, or by 
members of the public, or as a result of professionals following clinical 
guidelines or other policies etc; qualitative improvements in the processes of 
delivering the services; cost savings; and increases in health equity. 
-  Broader Social and Economic Benefits: includes benefits that can arise from 
the commercialisation of research in terms of spin-off companies, 
employment, exports, import substitution etc; and benefits gained from having 
a healthy workforce 
-  Overall score: your assessment of the overall impact of the work across all 
payback categories combined according to your opinion of their relative value. 
-  Value for Money: your assessment of the value for money provided to society 
given the size of grant awarded taking into account your assessment of the 
overall impact and the resources used. We shall send to you by email a table 
indicating the size of each grant in a directly comparable currency. 
In order to help you score these case studies, we provide a range of materials 
summarising our findings for each case study as follows: 
-  Payback table: Summarises key outputs of the case study under each of the 
categories listed above. We anticipate the summary table will be the main input 
to scoring. This also includes a summary of comments from peer reviewers. 
-   Case study summary table: Summarises the case study narrative, organised by 
stage of the research process. Each section can be cross referenced back to the 
full case study text, and gives a fuller explanation of the context than the 
payback table, with additional background material. 
-  Peer review summary table: Summarises the comments received from peer 
reviewers on the accuracy and clarity of each case study, with particular focus 
on comments about the level of impact and degree of leadership in the field. 
-   Bibliometrics data: Key data for each case study presented as a series of charts 
-   Coding data: Summary of the key features of the research and outputs from 
each case study across 2 of the 5 categories. 
In addition, an electronic copy of the full case study text and the full comments 
from peer review are provided for all case studies. We do not expect you will read 
all the case studies or peer review comments in full; rather, they can be used for 
reference and clarification where necessary as a supplement to the summary data 
provided for scoring.  
At the scoring workshop, you will have the opportunity to discuss the scoring 
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misunderstanding. You will then be able to score the case studies for a second time. 
However, if you do have any questions or queries, do not hesitate to contact us.  
We would be grateful if you could return your completed scoring form (by post or 
in electronic format) to reach us by 9am GMT on the 1st February. This will allow 
us to complete our initial analysis and prepare materials for the scoring workshop 
on the 11th/12th February. 
Many thanks for your time and efforts. We hope that you will find the process 
interesting and enjoyable. If you do have any queries please do not hesitate to 
contact us at any time. 